

个人简历

<https://sph.pku.edu.cn/info/1411/4181.htm>

<https://peerj.com/Cuifuq/>

https://www.researchgate.net/profile/Fuqiang_Cui

姓名：崔富强

出生年月：1971年9月

现任职务

北京大学公共卫生学院卫生检验学系主任，研究员，博士生导师。从事公共卫生与预防医学 25 年，主要研究领域为传染病流行病学，重点研究疫苗可预防疾病的流行病学、免疫预防、乙肝病毒的母婴阻断、高危人群免疫等。承担了国家“十五”科技攻关、“十一五”、“十二五”、“十三五”艾滋病和病毒性肝炎等传染病防治重大专项课题研究。发病论文 280 多篇，其中以第一作者或通讯作者发表同行评议论文 110 多篇，主编专著 3 部，主译著作 1 部。参与制定国家行业诊断标准 2 项。崔富强是世界卫生组织总部病毒性肝炎战略信息高级顾问，西太区乙肝专家组（Expert Resource Panel）成员，世界卫生组织总部疫苗十年行动计划工作组（Working group of Decade of Vaccine）成员、全球消除肝炎联盟第一届专家委员会委员。中国科协国际联络部联合国咨商生命科学与人类健康专委会专家，国家发展和改革委员会药品价格评价中心专家，中国肝炎防治基金会理事会理事，中华预防医学会促进消除病毒性肝炎工作委员会主任委员、中华预防医学会感染性疾病防控分会副主任委员、中华预防医学会疫苗临床研究专委会副主任委员，中国疫苗行业协会肝炎防控分会主任委员，中华预防医学会医疗机构公共卫生管理分会常委、疫苗和免疫分委会常委、卫生检验分会常委、全球卫生分会青年委员会副主任委员，中华医学会公共卫生分会第九届委员会委员、青年委员会副主任委员，中华医学会预防接种不良反应专家委员会委员，《中国预防医学杂志》主编、《中国病毒病杂志》副主编、《柳叶刀传染病学》中文版编委，《疫苗学》中文版编委、《中国疫苗和免疫》常务编委、《中华预防医学杂志》编委。

教育背景

2015 年毕业于新加坡国立大学李光耀公共政策学院，获公共管理硕士（与哈佛大学肯尼迪政府学院联合培养）（李光耀总理奖学金全额资助）（杰出校友提名奖）。

2012 年毕业于瑞士巴塞尔大学热带病与公共卫生学院，获流行病学博士（科研型）（巴塞尔大学全额资助）。

2004 年毕业于以色列希伯来大学公共卫生学院，获公共卫生硕士学位（希伯来大学奖学金全额资助）。

1995 年毕业于兰州大学公共卫生学院，获医学学士学位（优秀毕业生，杰出校友）。

工作经历

2020年8月~ 北京大学公共卫生学院 研究员 系主任 博士生导师

2019年8月~2020年8月 世界卫生组织总部全球病毒性肝炎项目高级技术官员。

2019年5月~2019年8月 国家卫生健康委国际合作司 高级顾问。

2016年11月~2019年5月 北京大学公共卫生学院 研究员/博士研究生导师。

2011年12月~2016年11月 中国疾病预防控制中心免疫规划中心副主任，研究员。

2005年~2012年 卫生部/全球疫苗和免疫联盟合作项目 中方主管

2005年7月~2011年12月在中国疾病预防控制中心免疫规划中心工作，任流行病二室（肝炎室）副主任、主任；副研究员，研究员。

2001年9月~2005年6月在甘肃省疾病预防控制中心免疫规划科工作，任副科长，主管医师。

1995年6月~2001年8月，在甘肃省卫生防疫站工作，医师。

社会兼职

- 《中国预防医学杂志》主编
- 《中国病毒病杂志》副主编
- 中华预防医学会疫苗临床研究专委会副主任委员（2020-2025）
- 中国疫苗行业协会肝炎防控分会主任委员（2021-2025）
- 中华预防医学会感染性疾病防控分会副主任委员（2018-2023）
- 比尔盖茨基金会《中国疫苗学培训项目》专家指导委员会委员（2018-2021）
- 中华医学会公共卫生分会委员（2018-2021）
- 中华预防医学会医疗机构公共卫生管理分会常委（2017-2020）
- 中华预防医学会卫生检验分会常委（2017-2020）
- 中华预防医学会疫苗和免疫分会常委（2017-2020）
- 中华预防医学会全球卫生分会青年委员会副主任委员（2017-2020）
- 中国科协国际联络部联合国咨商生命科学与人类健康专委会专家（2016-2020）
- 世界卫生组织西太区乙肝专家组成员（2015-2019）
- 中华医学会公共卫生分会第九届委员会青年委员会副主任委员（2015-2017）
- 中华医学会预防接种不良反应专家委员会委员（2014-2017）
- 中国卫生经济学会公共卫生分会委员（2013-2016）
- 中华医学会公共卫生分会第八届委员会青年委员会常委（2013-2015）
- 国家发展和改革委员会药品价格评价中心专家（2012-2015）
- WHO 免疫战略专家咨询委员会疫苗十年行动计划专家组成员（2013-2016）
- WHO 全球病毒性肝炎工作网络专家组成员（2012）
- 2012年西太区免疫专家咨询委员会成员（TAG）（代理）

- 卫生部疾控专家委员会免疫规划分委会秘书（2009-2012）
- 中国肝炎防治基金会专家委员会委员（2009-2012）（2013-2016）
- 《柳叶刀传染病学》中文版编委
- 《疫苗学》中文版编委
- 《中国疫苗和免疫》常务编委
- 《中华预防医学杂志》编委
- 《中国病毒病杂志》编委
- 《中国输血杂志》编委

承担的科研项目及资助情况

1. “十三五”传染病科技重大专项，《中国糖尿病人群乙肝病毒感染现状及乙肝疫苗免疫预防效果评价》，2018-2020,134.08 万元。项目号:2018ZX10721202。
2. 病原微生物生物安全国家重点实验室开放课题《儿童急性呼吸道感染中流感嗜血杆菌生物被膜状态下耐药机制研究》，2018-2020,20 万元。项目号: SKLPBS1836。
3. 国家自然科学基金，2016-2019，《我国乙肝病毒的分子进化趋势及其对宏观传播动力学的影响》，13.058 万元。项目号: 11571272
4. “十二五”科技重大专项: 2012 年,《我国乙型病毒性肝炎免疫预防新策略研究》,子课题负责人,经费 834.69 万元,项目号: 2012ZX10002001
5. “十一五”科技重大专项:2009 年,《我国乙型病毒性肝炎免疫预防策略研究》,子课题负责人,经费 1965 万。项目号: 2008ZX10002-001
6. “十五”科技攻关课题, 2006 年,《我国乙型肝炎流行规律研究》130 万,项目号: 2004BA718B01

获奖情况

- 1.中国新生儿乙肝疫苗预防接种关键技术的研究和应用项目获得 2017 年中华预防医学科学技术二等奖;
 - 2.应对输入脊髓灰质炎野病毒关键技术体系的研究及应用获得 2017 年华夏医学科技三等奖。
 3. 2012 年在新疆脊灰疫情防控中表现优秀,被卫生部授予新疆脊灰疫情防控先进个人。
 4. 2007 年-2011 年连续 5 年获得中国疾病预防控制中心优秀个人
 - 5.《我国乙型病毒性肝炎流行规律和防治对策研究》获得 2011 年中华预防医学科学技术二等奖,排名第二,证书号 20110103-2-G1002。
 - 6.《甘肃省不同经济地区儿童计划接种率及影响因素研究》获 2003 年甘肃省科学技术奖励委员会三等奖,证书号 2002-3-070/3
 - 7.《甘肃省消灭脊髓灰质炎系统工程研究》获 2003 年甘肃省科学技术奖励委员会二等奖,证书号 2002-2-037/8
- 2018 年北京大学公共卫生学院优秀党员

2018 年北京大学公共卫生学院科研工作三等奖
2017 年北京大学公共卫生学院科研工作三等奖。

参与制定的主要文件

1. 主编《疫苗上市后临床研究与评价》，2020，北京大学医学出版社。
2. 主编《卫生微生物学教程》，2020，北京大学医学出版社。
3. 主编. 《呼吸道合孢病毒感染》，科学出版社，2018 年，主编。
4. 主译《公共卫生实践中的流行病学》，2018，人民卫生出版社。
5. 参与《乙型病毒性肝炎诊断标准-WS 299-2008》制定。
6. 参与《流行性脑脊髓膜炎诊断标准-WS-295-2019》制定。
7. 参与 WHO 《Technical Consideration and case definitions to improve surveillance for viral hepatitis》、《Standard operating procedures for enhanced reporting of cases of acute hepatitis》和《Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection》技术指南的制定。
8. 参与《慢性乙型肝炎防治指南-2019》的制定。
9. 参与编写《子宫颈癌的预防》、《预防接种理论与实践》、《全国人群乙型病毒性肝炎血清流行病学调查报告》、《我国长远健康问题》、《疫苗价值》等 5 部论著。
10. 参与翻译《疫苗学》第五版。

主要第一或者通讯的英文论著

1. Zheng Hui, Shevanthi Nayagam, Polin Chan, Wang Fuzhen, Mark Thursz, Yin Zundong, Miao Ning, Sun Xiaojin, **Fuqiang Cui**, Zhang Guomind & Timothy B Hallett. Progress towards elimination of mother-to-child transmission of hepatitis B virus infection in China: a modelling analysis. Bull World Health Organ 2020;98:. (通讯作者)
2. **Cui F**. Strategies to increase timely uptake of hepatitis B vaccine birth dose. Lancet Glob Health. 2020 Jul;8(7): e869-e870.
3. Han B, Zhao T, Liu B, Liu H, Zheng H, Wan Y, Qiu J, Zhuang H, **Cui F**. Public Awareness, Individual Prevention Practice, and Psychological Effect at the Beginning of the COVID-19 Outbreak in China. J Epidemiol. 2020 Oct 5;30(10):474-482. (通讯作者)
4. Zhao TS, Du J, Li HJ, Cui Y, Liu Y, Yang Y, **Cui F**, Lu QB. Molecular epidemiology and clinical characteristics of herpangina children in Beijing, China: a surveillance study. PeerJ. 2020 Oct 15;8:e9991. (通讯作者)
5. Xu MY, Ma JH, Du J, Yin J, Liu L, **Cui F**, Lu QB. Nonalcoholic Fatty Liver Disease Is Associated with Helicobacter pylori Infection in North Urban Chinese: A Retrospective Study. Gastroenterol Res Pract. 2020 Jan 25;2020:9797841. (通讯作者)
6. Wang S, Han B, Wan Y, Liu J, Zhao T, Liu H, **Cui F**. Do Male University Students Know Enough About Human Papillomavirus (HPV) to Make Informed Decisions About Vaccination? Med Sci Monit. 2020 Jun 30;26:e924840. (通讯作者)
7. Li HJ, Du J, Yang YN, Cui Y, Xi L, Wang S, Liu YQ, Zhang GF, **Cui F**, Lu QB. Outbreak of Human Parainfluenza Virus Type 1 in a Kindergarten from China, 2018. Journal of Pediatric Infectious Diseases. 2020 Jan;15(01):025-30. (通讯作者)

8. Zhao TS, Du J, Sun DP, Zhu QR, Chen LY, Ye C, Wang S, Liu YQ, **Cui F**, Lu QB. A review and meta-analysis of the epidemiology and clinical presentation of coxsackievirus A6 causing hand-foot-mouth disease in China and global implications. *Rev Med Virol.* 2020 Mar;30(2):e2087. (通讯作者)
9. Zheng H, Zhang G, Wang F, Yin Z, Miao N, Sun X, Liang X, **Cui F**. Self-motivated medical care-seeking behaviors and disease progression in a community-based cohort of chronic hepatitis B virus-infected patients in China. *BMC public health.* 2019 Dec 1;19(1):901. (通讯作者)
10. Yuan Q, Wang F, Zheng H, Zhang G, Miao N, Sun X, Woodring J, Chan PL, **Cui F**. Hepatitis B vaccination coverage among health care workers in China. *PLoS One.* 2019 May 7;14(5):e0216598. (通讯作者)
11. Han B, Wang S, Wan Y, Liu J, Zhao T, Cui J, Zhuang H, **Cui F**. Has the public lost confidence in vaccines because of a vaccine scandal in China. *Vaccine.* 2019 Aug 23;37(36):5270-5. (通讯作者)
12. **Cui F**, Woodring J, Chan P, Xu F. Considerations of antiviral treatment to interrupt mother-to-child transmission of hepatitis B virus in China. *Int J Epidemiol.* 2018 Oct 1;47(5):1529-1537.
13. Han B, Yuan Q, Shi Y, Wei L, Hou J, Shang J, Han Y, Jin C, Chan PL, Zhuang H, Li J, **Cui F**. The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China. *PLoS One.* 2018 Apr 12;13(4): e0195455. (通讯作者)
14. Zheng H, **Cui FQ**, Wang FZ, Huang LF, Shao XP, Du JF, Li J, Zhou Y, Zheng HZ, Zhuo JT, Zeng XX, Zhang GM, Miao N, Sun XJ, Liang XF, Luo HM. The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China. *J Viral Hepat.* 2018 Jan;25(1):88-96. (共同一作)
15. **Cui F**, Shen L, Li L, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy, China: [J]. *Emerging Infectious Diseases*, 2017, 23(5):765-772.
16. Wang F, Zhang G, Zheng H, Miao N, Shen L, Wang F, Dong P, Du F, Chen C, Zhang X, **Cui F**. Post-vaccination serologic testing of infants born to hepatitis B surface antigen positive mothers in 4 provinces of China. *Vaccine.* 2017 Jul 24;35(33):4229-4235. (通讯作者)
17. Wang F, Zheng H, Zhang G, Ding Z, Li F, Zhong G, Chen Y, Jia Y, Miao N, Wu Z, Sun X, Li L, Liang X, **Cui F**. Effectiveness of prevention of mother-to-child transmission practice in three provinces of Southern China. *Hum Vaccin Immunother.* 2015;11(8):2061-7. (通讯作者)
18. **Cui F**, Liang X, Wang F, Zheng H, Hutin Y, Yang W. Chinese Experience with Development, Production and Post-marketing Surveillance of Hepatitis A vaccines. *J Epidemiol*, 2014, 24(2):169-177.
19. Jia Z, Yi Y, Liu J, Cao J, Zhang Y, Tian R, Yu T, Wang H, Wang X, Su Q, Zhou W, **Cui F**, Liang X, Bi S. Epidemiology of hepatitis E virus in China: results from the Third National Viral Hepatitis Prevalence Survey, 2005-2006. *PLoS One.* 2014 Oct 31;9(10):e110837. (通讯作者)
20. Jia YX, **Cui FQ**, Li L, Zhang DL, Zhang GM, Wang FZ, Gong XH, Zheng H, Wu ZH, Miao N, Sun XJ, Zhang L, Lv JJ, Yang F. Comparison between the EQ-5D-5L and the EQ-5D-3L in patients with hepatitis B. *Qual Life Res.* 2014 Oct;23(8):2355-63. (通讯作者)
21. Liang X, **Cui F**, Hadler S, Wang X, Luo H, Chen Y, Kane M, Shapiro C, Yang W, Wang Y.

- Origins, design and implementation of the China GAVI project. *Vaccine*. 2013 Dec 27;31 Suppl 9:J8-14. (共同一作)
22. Cui F, Liang X, Gong X, Chen Y, Wang F, Zheng H, Wu Z, Miao N, Hadler SC, Hutin YJ, Luo H, Yang W. Preventing hepatitis B through universal vaccination: reduction of inequalities through the GAVI China project. *Vaccine*. 2013 Dec 27;31 Suppl 9:J29-35.
 23. Cui F, Luo H, Wang F, et al. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: Results from GAVI Final evaluation. *Vaccine*, 2013, 31 S (30) J36– J42.
 24. Wu Z, Cui F, Chen Y, Miao N, Gong X, Luo H, Wang F, Zheng H, Kane M, Hadler SC, Hutin YJ, Liang X, Yang W. Evaluation of immunization injection safety in China, 2010: achievements, future sustainability. *Vaccine*. 2013 Dec 27;31 Suppl 9:J43-8. (通讯作者)
 25. Cui F, Li L, Hadler S, et al. Reprint of: Factors associated with effectiveness of the first dose of hepatitis B vaccine in China: 1992–200. *Vaccine*, 2013, 31S(30) J56– J61.
 26. Yang W, Liang X, Cui F, Li L, Hadler SC, Hutin YJ, Kane M, Wang Y. Key outcomes and addressing remaining challenges--perspectives from a final evaluation of the China GAVI project. *Vaccine*. 2013 Dec 27;31 Suppl 9:J73-8. (共同一作)
 27. Cui F, Drobeniuc J, Hadler S, Hutin YJ, Ma F, Wiersma S, Wang F, Wu J, Zheng H, Zhou L, Zuo S. Review of hepatitis B surveillance in China: Improving information to frame future directions in prevention and control. *Vaccine*, 2013, 31S(30) J79– J84.
 28. Cui F, Luo H, Zhou L, et al. Transmission of Pandemic Influenza A(H1N1) Virus in a Train in China. *J Epidemiol*, 2011, 21(4):271-277.
 29. Cui F, Li L, Hadler S, Wang F, et al. Factors Associated with Effectiveness of the First Dose of Hepatitis B Vaccine in China:1992-2005. *Vaccine*, 2010, 38(37):5973–5978.
 30. Cui F, Hadler S, Zheng H, et al. Status of hepatitis A surveillance and vaccine use in China from1990 through2007. *J Epidemiol*, 2009, 19(4):189-195.
 31. Cui F, Wang X, Cao L, Liang X, Lu Y, Hu Y, Hadler S, Shapiro CN, Wiersma ST, Ward JW. Progress in Hepatitis B Prevention Through Universal Infant Immunization — China, 1997–2006. *MMWR*, 2007, 56(18): 441-445.
 32. Cui F, Wang X, Cao L, et al. Progress in Hepatitis B Prevention Through Universal Infant Vaccination-China, 1997-2006. *Wkly Epidemiol Rec*, 2007, 82(24):209-224.
 33. Cui F, Wang X, Cao L, et al. Progress in Hepatitis B Prevention Through Universal Infant Vaccination-China, 1997-2006. *JAMA*, 2007, 298(5): 506-509.
 34. Cui F, Gaofin R. Immunization coverage and its determinants in children aged 12–23 months in Gansu, China. *Vaccine*, 2007, 25(4):664-671.
 35. Cui F, Liang X, Cao L, et al. Improving Hepatitis B immunization rates in China. *J Clin Virol*, 2006, 36(s):237.

以第一作者或通讯作者发表的中文论文

1. 韩冰峰,杜娟,王帅,赵天朔,刘贝,刘武,杨树博,刘雅琼,崔富强.成人糖尿病患者乙型肝炎疫苗免疫应答效果 Meta 分析[J].中国疫苗和免疫,2020,26(05):578-582. (通讯作者)
2. 赵天朔,杜娟,刘翰谕,刘雅琼,崔富强,卢庆彬.疱疹性咽峡炎流行病学及病原学研究进展[J].中国病毒病杂志,2020,10(05):385-390. (通讯作者)
3. 万咏梅,范晨璐,刘宇德,徐靓亮,赵天朔,邱佳裔,王富珍,张伟,孔庆福,张国民,崔富强.黑龙江

- 江和甘肃省成人乙型肝炎疫苗接种现状和影响因素[J].中国疫苗和免疫,2020,26(02):207-212. (通讯作者)
4. 万咏梅,王富珍,郑徽,张国民,张卫,姚军,崔富强.20-49岁成人乙型肝炎疫苗不同免疫程序的免疫原性比较[J].中国疫苗和免疫,2020,26(01):19-24. (通讯作者)
 5. 崔富强.乙型肝炎疫苗免疫是预防HBV母婴传播的关键——对《中国乙型肝炎病毒母婴传播防治指南(2019年版)》的管见[J].临床肝胆病杂志,2020,36(02):305-306.
 6. 韩冰峰,袁千里,刘姜,刘雅琼,黄宁华,崔富强.我国4个省份慢性乙型肝炎患者受到性与生育歧视现状调查[J].中华流行病学杂志,2020,41(4):504-507. (通讯作者)
 7. 赵春艳,石晶,苗良,徐颖,王宝兰,崔富强,孙远洁.1起接种乙型肝炎疫苗后偶合间质性肺炎死亡案例分析[J].中国疫苗和免疫,2019,25(01):115-117. (通讯作者)
 8. 崔富强.中国建国以来病毒性肝炎的防控成就[J].国际病毒学杂志,2019(05):289-290-291-292.
 9. 万咏梅,王富珍,张国民,崔富强.成人乙型肝炎感染风险和疾病负担[J].中国疫苗和免疫,2019,25(05):611-616. (通讯作者)
 10. 崔富强,庄辉.我国新生儿乙型肝炎母婴阻断成就和展望[J].中国病毒病杂志,2019,9(05):321-326.
 11. 崔富强.中国儿童用联合疫苗免疫策略的探讨[J].中国病毒病杂志,2019,9(03):161-166.
 12. 万咏梅,王富珍,张国民,崔富强.西太平洋地区十个岛屿国家艾滋病与梅毒和乙型肝炎防治现状[J].中国预防医学杂志,2019,20(10):1000-1004. (通讯作者)
 13. 韩冰峰,杨树博,张入学,崔富强.2型糖尿病和空腹血糖受损与肝功能指标的相关性研究[J].中国预防医学杂志,2019,20(06):505-509. (通讯作者)
 14. 韩冰峰,袁千里,刘姜,刘雅琼,黄宁华,崔富强.中国4省慢性乙型肝炎患者反歧视法律及政策知晓情况及维权意识[J].中国公共卫生:1-4. (通讯作者)
 15. 韩冰峰,袁千里,刘姜,崔富强.糖尿病患者感染HBV风险的Meta分析[J].中华预防医学杂志,2018,52(07):748-752. (通讯作者)
 16. 韩冰峰,崔富强.国产肠道病毒71型灭活疫苗临床免疫原性研究进展[J].中国疫苗和免疫,2017(4):471-476. (通讯作者)
 17. 王富珍,郑徽,张国民,缪宁,孙校金,崔富强.中国2014年HBsAg阳性母亲所生1~14岁儿童乙型肝炎血清流行病学特征分析[J].中华流行病学杂志,2017,38(04):457-461. (通讯作者)
 18. 缪宁,张国民,王富珍,郑徽,孙校金,马小军,崔富强.中国6省市急性乙型病毒性肝炎住院病例诊断与报告一致性分析[J].中华流行病学杂志,2017,38(02):216-220. (通讯作者)
 19. 王富珍,张国民,沈立萍,刘建华,郑徽,王锋,缪宁,孙校金,梁晓峰,崔富强.中国1~4岁儿童首针乙型肝炎疫苗未及时接种者特征及影响因素分析[J].中华流行病学杂志,2017,38(1):32-36. (通讯作者)
 20. 王富珍,郑徽,缪宁,孙校金,张国民,梁晓峰,崔富强.中国1994—2001年出生人群乙型肝炎疫苗补种前后乙型肝炎血清流行病学特征分析[J].中华预防医学杂志,2017,51(6):469-474. (通讯作者)
 21. 马小军,王富珍,郑徽,张国民,巴文生,阿克忠,蔡芝锋,郝增平,崔富强.青海省三个地区乙型肝炎病毒表面抗原阳性母亲所生婴儿免疫后血清学检测现状[J].中国疫苗和免疫,2017,23(05):503-507. (通讯作者)
 22. 郑徽,王富珍,张国民,缪宁,孙校金,崔富强.2006和2014年中国1~29岁乙型肝炎病毒易感人群的流行病学特征分析[J].中华预防医学杂志,2017,51(07):581-586. (通讯作者)
 23. 袁千里,孙校金,崔富强.中国医务人员乙型肝炎病毒感染与乙型肝炎疫苗接种现状[J].

- 中国疫苗和免疫, 2016(6):702-707. (通讯作者)
24. 周羚, 崔富强, 潘毅. 重论预防接种的重要性[J]. 中华预防医学杂志, 2016, 50(9):755-758. (通讯作者)
 25. 崔富强, 庄辉. 我国乙型肝炎防控工作进展、挑战及对策[J]. 中国病毒病杂志, 2016(2):81-87.
 26. 崔富强. 全球扩大免疫规划实施进展回顾[J]. 中国疫苗和免疫, 2016(2):121-124.
 27. 郑徽, 王富珍, 张国民, 吴振华, 缪宁, 孙晓金, 王华庆, 崔富强, 梁晓峰. 中国社区成年人群 HBsAg 阳性者医疗和就诊行为及相关影响因素研究. 中华流行病学杂志, 2016, 37(4): 455-459. (通讯作者)
 28. 王富珍, 郑徽, 刘建华, 孙校金, 缪宁, 沈立萍, 张国民, 崔富强. 中国 2014 年 2~29 岁人群甲型肝炎疫苗接种率及甲型肝炎报告发病分析[J]. 中华流行病学杂志, 2016, 37(8):1099-1104. (通讯作者)
 29. 郑徽, 王富珍, 张国民, 缪宁, 孙校金, 崔富强. 2011-2013 年全国传染病报告信息管理系统中乙型肝炎病例重复报告现状分析[J]. 中华流行病学杂志, 2016, 37(9):1248-1252. (通讯作者)
 30. 郑徽, 王富珍, 张国民, 吴振华, 缪宁, 孙校金, 王华庆, 崔富强, 梁晓峰. 中国社区成年人群 HBsAg 阳性者医疗和就诊行为及相关影响因素研究[J]. 中华流行病学杂志, 2016, 37(4):455-459. (通讯作者)
 31. 王富珍, 郑徽, 张国民, 缪宁, 陈园生, 吴振华, 孙校金, 李黎, 梁晓峰, 崔富强. 8 个省(自治区)乙型肝炎病毒表面抗原阳性产妇筛查及新生儿免疫预防措施的调查[J]. 中国疫苗和免疫, 2014, (6) :523-528. (通讯作者)
 32. 蒋燕, 余文周, 张晓华, 王蕾, 周玉清, 张旋, 安志杰, 李克莉, 许涤沙, 王华庆, 崔颖, 崔富强, 李黎. 2013 年媒体报道乙型肝炎疫苗事件后公众对预防接种信任度的电话调查分析[J]. 中国疫苗和免疫, 2014, (4) :314-380. (通讯作者) .
 33. 王富珍, 崔富强. 乙型肝炎病毒母婴阻断免疫预防策略综述[J]. 中国疫苗和免疫, 2014, (4) :355-375. (通讯作者) .
 34. 郑徽, 王富珍, 沈立萍, 张国民, 王锋, 陈园生, 龚晓红, 崔富强, 梁晓峰. 慢性乙型肝炎病例乙型肝炎病毒脱氧核糖核酸载量和乙型肝炎病毒 e 抗原状态与丙氨酸氨基转移酶的相关性研究[J]. 中国疫苗和免疫, 2014, (4) :294-323. (通讯作者) .
 35. 崔富强, 杨维中. 乙型肝炎疫苗接种与疑似预防接种不良反应. 中华流行病学杂志, 2014, 35(1):1-2.
 36. 周羚, 崔富强, 汤奋扬. 中国新生儿乙型肝炎疫苗首针接种现状、影响因素及对策, 中华预防医学杂志, 48(6):437-40. (通讯作者)。
 37. 雷正龙, 崔富强. 有计划的预防接种是提高国民健康水平的重要保障, 中华预防医学杂志, 2014 ;48(6):433-6. (通讯作者)。
 38. 徐也晴, 崔富强, 张国民, 缪宁, 吴振华, 郑徽, 王富珍, 孙校金. 中国 2007~2011 年甲型和戊型病毒性肝炎以及细菌性痢疾流行病学特征分析. 中国疫苗和免疫, 2013, 19(5):501-506. (通讯作者)
 39. 缪宁, 张国民, 王富珍, 郑徽, 吴振华, 孙校金, 龚晓红, 崔富强. 中国 2004~2011 年戊型病毒性肝炎流行病学特征分析. 中国疫苗和免疫, 2013, 19(5):451-454. (通讯作者)
 40. 王富珍, 张国民, 郑徽, 高培, 曹凤瑞, 蒋征刚, 颜丙玉, 范军星, 邵晓萍, 陈筱纯, 张晓曙, 龚晓红, 缪宁, 陈园生, 孙校金, 梁晓峰, 崔富强. 2008-2010 年 18 个县乙型病毒性肝炎监测试点县报告病例结果分析. 中国疫苗和免疫, 2013, 19(5):439-443. (通讯作者)
 41. 缪宁, 王富珍, 陈园生, 郑徽, 吴振华, 龚晓红, 崔富强. 中国 24 县的基层预防接种人员对乙

- 型病毒性肝炎相关知识和态度的调查分析.中国疫苗和免疫,2013,19(4):329-331.通讯作者)
42. 崔富强, 张国民, 孙校金. 中国 15~59 岁人群乙型肝炎病毒感染易感性分析,江苏预防医学, 2013, 24(4):1-3.
 43. 张国民,孙校金,王富珍,郑徽,龚晓红,缪宁,贾元熙,吴振华,崔富强.中国 18~59 岁人群乙型病毒性肝炎流行病学特征分析及乙型肝炎疫苗免疫策略探讨.中国疫苗和免疫, 2013, 19(3): 266-270.(通讯作者)
 44. 梁晓峰,崔富强.中国成人乙型肝炎免疫预防技术指南.胃肠病学和肝病杂志, 2012,21(3):197-201.
 45. 徐也晴,崔富强,罗建,缪宁,孙校金,石峰.西北五省(自治区)2011 年甲型病毒性肝炎流行病学特征分析.中国疫苗和免疫,2012,18(6):546-549.(通讯作者)
 46. 马汉平,何健,崔富强,王宇红,龚晓红,陈园生,王富珍,郑徽,吴振华,缪宁,孙校金. 甘肃省某三级甲等医院医务人员乙型病毒性肝炎知识 态度 行为调查. 中国疫苗和免疫,2012,18(5):461-480. (通讯作者)
 47. 崔富强, 王富珍, 吴振华, 龚晓红, 陈园生, 郑徽, 缪宁.中国 2005~2010 年报告乙型病毒性肝炎发病分析.中国疫苗和免疫, 2011, 17(6):483-486.
 48. 崔富强. 我国乙型肝炎疫苗最佳免疫策略研究.第 15 届全国病毒性肝炎及肝病议.2011.
 49. 崔富强,龚晓红,陈园生,王富珍,郑徽,胡苑笙,吴振华,缪宁,李黎,梁晓峰.中华人民共和国卫生部/全球疫苗和免疫联盟合作项目地区乙型肝炎疫苗纳入免疫规划效果评估.中国疫苗和免疫,2009,15(4):289-293.
 50. 崔富强,毕胜利,张勇,龚晓红,陈园生,王富珍,郑徽,贾志远,胡苑笙,吴振华,缪宁,李黎,梁晓峰.中国人群大样本调查乙型肝炎病毒感染血清学标志物检出模式分析.中国疫苗和免疫,2009,15(4):294-299.
 51. 郑徽,崔富强.甲型肝炎减毒活疫苗与灭活疫苗免疫原性及其影响因素.中国疫苗和免疫,2009,15(4):371-374. (通讯作者)
 52. 崔富强,缪宁,胡苑笙,吴振华,段佳丽,钟继荣,王小玲,李敬华.北京和甘肃小学生病毒性肝炎健康促进项目效果评价.中国疫苗和免疫,2009,15(5): 409-416.
 53. 崔富强,龚晓红,陈园生,王富珍,郑徽,胡苑笙,吴振华,王华庆,梁晓峰.中国乙型肝炎疫苗免疫策略及新生儿以外人群接种乙型肝炎疫苗可行性分析. 中国疫苗和免疫 2008,14(6):553-558.
 54. 崔富强, 王富珍, 郑徽, 陈园生, 龚晓红, 王华庆, 梁晓峰.中国 2005~2007 年乙型病毒性肝炎发病分析. 中国疫苗和免疫,2008,14(5):413-417.
 55. 崔富强,卢永,王富珍,陈园生,郑徽,张勇,龚晓红,韩丽丽,董红军,陈超,凌罗亚,张丽,刁琳琪,邵晓萍,方刚,高丽,梁晓峰.中国 2006 年乙型肝炎报告病例构成分析,中华流行病学杂志, 2007,28(9):872-874.
 56. 崔富强,胡苑笙,卢永, 普尔哈提,陈园生,李继军,郑徽.中国西部地区不同出生地点新生儿乙型肝炎疫苗首针及时接种情况分析.中国计划免疫,2007,13(4): 313-315
 57. 崔富强,王富珍,郑徽,陈园生,李继军,龚晓红,方挺,高丽,张勇,梁晓峰. 接种不同剂量重组乙型肝炎疫苗(酵母)阻断乙型肝炎病毒母婴传播的评价.中国计划免疫,2007,13(4): 289-292.
 58. 崔富强,李庭栋,郭强.预防接种率调查评估比较.中国计划免疫,2007,13(2): 170-174.
 59. 崔富强, 李廷栋, 郭强. 预防接种率调查评估结果比较.中国疫苗和免疫,2007,13(2): 170-174.
 60. 崔富强,甫尔哈提, Stephen Hadler, 梁晓峰.中国不同地区产妇住院分娩率与新生儿乙型

肝炎疫苗接种率分析.中国计划免疫,2007,13(1): 1-3.

61. 崔富强,卢永,胡苑笙,陈园生,Steve Hadler,曹玲生,梁晓峰,崔钢,中国乙型肝炎疫苗纳入儿童免疫规划实施情况调查分析,中国计划免疫,2006,12(4):241-245.
62. 崔富强,王晓军,梁晓峰.中国≤15 岁人群乙型病毒性肝炎发病流行病学分析.中国计划免疫,2006,12(3): 206-208.
63. 崔富强,梁晓峰,卢永,Steve Hadler. 中国西部 12 个省(自治区、直辖市)乙型肝炎疫苗接种情况分析.中国计划免疫,2006,12(2): 81-83.
64. 崔富强,李慧,孟蕾,王健,刘建地,李凤琴,卢欣婷,署爱霞. 甘肃省 12-23 月龄儿童免疫接种率及影响因素研究.国家科技成果,2005.
65. 崔富强,唐宇,卢欣婷,张宁静.甘肃省计划免疫冷链系统计算机建档管理模式探讨.中国计划免疫,2003,9(5):258.
66. 崔富强, 邸宏杰, 何庚生, 等. 甘肃省消灭脊髓灰质炎工作进展. 中国计划免疫, 2002, 8(s): 17-18.
67. 崔富强,何庚声,李慧.甘肃省消除新生儿破伤风项目工作评.中国计划免疫, 2001,7(3):512-154.
68. 崔富强. 甘肃省冷链设备状况调查.中华流行病学杂志, 1997, 18(1-C): 141-145.

《中国卫生年鉴》系列 (5 篇)

69. 崔富强.全国乙肝防治工作(全国 15 岁以下人群乙肝疫苗补种项目). 中国卫生年鉴,2011.
70. 崔富强. 2009 年补种乙肝疫苗项目实施进展. 中国卫生年鉴 ,2010.
71. 崔富强. 全国乙肝防治工作进展. 中国卫生年鉴 ,2010.
72. 崔富强,崔钢. 2008 年乙肝控制工作. 中国卫生年鉴 ,2009.
73. 崔富强. 卫生部开展乙肝疫苗纳入计划免疫项目中期评估. 中国卫生年鉴 ,2006.

按年份发表的以其他位次作者发表的中英文论文(155 篇)

2020 年

1. Wang F, Sun X, Wang F, Zheng H, Jia Z, Zhang G, Bi S, Miao N, Zhang S, **Cui F**, Li L, Wang H, Liang X, Rodewald LE, Feng Z, Yin Z, Shen L. Changing Epidemiology of Hepatitis A in China: Evidence From Three National Serological Surveys and the National Notifiable Disease Reporting System. Hepatology. 2020 Jun 26.
2. Tan M, Bhadoria AS, **Cui F**, Tan A, Van Holten J, Easterbrook P, Ford N, Han Q, Lu Y, Bulterys M, Hutin Y. Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Nov 13:S2468-1253(20)30307-1.
3. Yin J, Liang P, Chen G, Wang F, **Cui F**, Liang X, Zhuang G. Tenofovir prophylaxis for preventing mother-to-child hepatitis B virus transmission in China: A cost-effectiveness analysis. Int J Infect Dis. 2020 Jun;95:118-124.

2019 年

4. 王富珍,孙校金,王锋,刘建华,张国民,郑徽,缪宁,张爽,张伟,毕胜利,崔富强,沈立萍,梁晓峰. 我国 2014 年 1~29 岁人群戊型肝炎血清流行病学特征分析[J].中华流行病学杂志,2019(11):1426-1427-1428-1429-1430-1431.
5. Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, Jia J, Mao Q, Li J, Li Z, Liu Z, Wei L, Xie Q, Yang X, Zhang H, Zhuang H. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clin Gastroenterol Hepatol. 2019 Sep;17(10):1929-1936.e1.
6. Yin XR, Liu ZH, Liu J, Liu YY, Xie L, Tao LB, Jia JD, Cui FQ, Zhuang GH, Hou JL. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China. Chin Med J (Engl). 2019 Oct 5;132(19):2315-2324.
7. 王贵强,王福生,庄辉,李太生,郑素军,赵鸿,段钟平,侯金林,贾继东,徐小元,崔富强,魏来.慢性乙型肝炎防治指南(2019 年版)[J].临床肝胆病杂志,2019,35(12):2648-2669.
8. 杜娟,孙文俊,房庚雨,王帅,刘雅琼,崔富强,卢庆彬.诺如病毒 GII.17 型流行特征和基因变异进化研究进展[J].中华医院感染学杂志,2019,29(23):3676-3680.
9. Miao N, Zheng H, Sun X, Shen L, Wang F, Cui F, Yin Z, Zhang G, Wang F. Enhanced sentinel surveillance for hepatitis B infection in 200 counties in China, 2013-2016. PLoS One. 2019 Apr 23;14(4):e0215580.
10. 李洪军,崔燕,杨艳娜,黄芳,杜娟,王帅,卢庆彬,崔富强,刘芬.2011—2018 年北京市通州区儿童急性呼吸道感染九种病毒性病原体监测研究[J].中国感染控制杂志,2019,18(08):713-718.

2018 年

11. Sun X, Wang F, Zheng H, Miao N, Yuan Q, Cui F, Yin Z, Zhang G, Levine H. The impact of expanded program on immunization with live attenuated and inactivated Hepatitis A vaccines in China, 2004-2016. Vaccine. 2018 Feb 28;36(10):1279-1284.
12. Zu J, Li M, Zhuang G, Liang P, Cui F, Wang F, Zheng H, Liang X. Estimating the impact of test-and-treat strategies on hepatitis B virus infection in China by using an age-structured mathematical model. Medicine (Baltimore). 2018 Apr;97(16):e0484.
13. Shan S, Cui F, Jia J. How to control highly endemic hepatitis B in Asia. Liver Int. 2018 Feb;38 Suppl 1:122-125.
14. 曾滢,陈鲁粤,杨忠华,汪婷婷,梁晓峰,王富珍,崔富强,杜伟民,蒋征刚,姚军.16 岁及以上人群接种 60 μ g 重组乙型肝炎疫苗安全性及免疫原性研究[J].预防医学,2017,29(09):869-873.
15. 陈万青,崔富强,樊春笋,李霓,曲春枫,舒为群,王宇婷,殷建华,邹怀宾.中国肝癌一级预防专家共识(2018)[J].中华肿瘤杂志,2018,40(07):550-557.

2017 年

16. Feng Y, Shi J, Gao L, et al. Immunogenicity and safety of high-dose hepatitis B vaccine among drug users: A randomized, open-labeled, blank-controlled trial. *Hum Vaccin Immunother.* Jun 3 2017;13(6):1-7.
17. Liu T, Wang F, Zhang S, et al. Whole-gene analysis of two groups of hepatitis B virus C/D inter-genotype recombinant strains isolated in Tibet, China. *PLoS One.* 2017;12(6):e0179846.
18. 吕静静, 颜丙玉, 刘甲野,等. 乙型肝炎疫苗基础免疫低应答婴儿再次免疫后 4 年抗体持久性观察[J]. *中华预防医学杂志*, 2017, 51(6):490-495.
19. 马起山, 梁森, 肖和卫,等. 中国 12 个地区乙型肝炎相关疾病住院患者经济负担调查[J]. *中华流行病学杂志*, 2017, 38(7):868-876.
20. 张丽, 张卫, 吕静静,等. 5 μ g 和 10 μ g 重组乙型肝炎疫苗初次免疫正常应答和高应答新生儿 5 年抗体持久性比较[J]. *中华流行病学杂志*, 2017, 38(9):1156-1160.
21. Zu J, Zhuang G, Liang P, et al. Estimating age-related incidence of HBsAg seroclearance in chronic hepatitis B virus infections of China by using a dynamic compartmental model. *Sci Rep.* Jun 6 2017;7(1):2912.
22. 曾滢, 陈鲁粤, 杨忠华,等. 16 岁及以上人群接种 60 μ g 重组乙肝疫苗安全性及免疫原性研究[J]. *浙江预防医学*, 2017, 29(9):869-873.

2016 年

23. 岳晨妍, 张旋, 褚尧竹, 段梦娟, 崔健, 崔富强, 李黎, 周玉清. 免疫规划工作人员对疫苗安全性及风险沟通意识的定性调查[J]. *中国健康教育*, 2016, 32(1):12-14, 48.
24. Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. *Vaccine.* Dec 7 2016;34(50):6158-6165.
25. Valdivieso F, Gonzalez C, Najera M, et al. Knowledge, attitudes, and practices regarding hantavirus disease and acceptance of a vaccine trial in rural communities of southern Chile. *Hum Vaccin Immunother.* Apr 3 2017;13(4):808-815.
26. Gao S, Zeng L, Zhang X, et al. Attenuated *Streptococcus pneumoniae* vaccine candidate SPY1 promotes dendritic cell activation and drives a Th1/Th17 response. *Immunol Lett.* Nov 2016;179:47-55.
27. Sheng Z, Gao N, Cui X, et al. Electroporation enhances protective immune response of a DNA vaccine against Japanese encephalitis in mice and pigs. *Vaccine.* Nov 11 2016;34(47):5751-5757.
28. Wang H, Cai B, Rao D, et al. Rapid immunization effects of a new type of 60 μ g hepatitis B vaccine compared with traditional 20 μ g hepatitis B vaccines in adults. *Hum Vaccin Immunother.* Nov 2016;12(11):2921-2926.
29. Wu D, Yen C, Yin ZD, et al. The Public Health Burden of Rotavirus Disease in Children Younger Than Five Years and Considerations for Rotavirus Vaccine Introduction in China. *Pediatr Infect Dis J.* Dec 2016;35(12):e392-e398.
30. 张丽, 颜丙玉, 吕静静, 刘甲野, 冯艺, 吴文龙, 曹传昭, 陈士玉, 周立波, 梁晓峰, 崔富强, 王富珍, 张国民, 徐爱强. 乙型肝炎疫苗初次免疫成年无应答者再次免疫后 4 年抗体持久性观察[J]. *中华预防医学杂志*, 2016, 50(6):497-502.
31. 吕静静, 殷修旺, 颜丙玉, 刘甲野, 冯艺, 吴文龙, 陈士玉, 周立波, 梁晓峰, 崔富强, 王富珍, 张丽, 徐爱强. 乙型肝炎疫苗初次免疫成年低应答者再次免疫后 4 年抗体持久性观察[J]. *中华预防医学杂志*, 2016, 50(6):491-496.

32. 吴文龙,颜丙玉,吕静静,刘甲野,冯艺,陈士玉,周立波,梁晓峰,崔富强,王富珍,张国民,张丽,徐爱强.乙型肝炎疫苗初次免疫成年正常应答和高应答者 5 年抗体持久性观察[J].中华预防医学杂志,2016,50(6):484-490.
33. 吕静静,张丽,颜丙玉,刘甲野,冯艺,宋立志,陈士玉,周立波,梁晓峰,崔富强,王富珍,徐爱强.乙型肝炎疫苗初次免疫成年正常应答和高应答者 3 年抗体持久性观察[J].中华预防医学杂志,2016,50(6):478-483.
34. Yue C, Sun X, Wei N, et al. Quick assessment of the influence of the Hepatitis B vaccine event on children's vaccination. *Hum Vaccin Immunother.* Oct 2 2016;12(10):2611-2615.
35. Yin WJ, Shen LP, Wang FZ, et al. Hepatitis B Immunoprophylactic Failure and Characteristics of the Hepatitis B Virus Gene in Mother-Infant Pairs in Parts of China. *Biomed Environ Sci.* Nov 2016;29(11):790-801.
36. Zhang X, An J, Tu A, et al. Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose. *Hum Vaccin Immunother.* Sep 2016;12(9):2322-2326.
37. Yu W, Liu D, Zheng J, et al. Loss of confidence in vaccines following media reports of infant deaths after hepatitis B vaccination in China. *Int J Epidemiol.* Apr 2016;45(2):441-449.
38. Chen YS, Zheng H, Liu YM, et al. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. *Hum Vaccin Immunother.* Jul 2 2016;12(7):1838-1846.
39. Zhang S, Ma Q, Liang S, et al. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. *J Viral Hepat.* Mar 2016;23(3):202-210.

2015 年

40. Liang P, Zu J, Yin J, Li H, Gao L, Cui F, et al. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis. *J Theor Biol.* 2015; 386: 115-21.
41. Wang F, Shen L, Cui F, Zhang S, Zheng H, Zhang Y, et al. The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. *Vaccine.* 2015; 33(23): 2704-9.
42. Zheng H, Wang FZ, Zhang GM, Cui FQ, Wu ZH, Miao N, et al. An economic analysis of adult hepatitis B vaccination in China. *Vaccine.* 2015; 33(48): 6831-9.
43. Zhang S, Ma Q, Liang S, Xiao H, Zhuang G, Zou Y, Tan H, Liu J, Zhang Y, Zhang L, Feng X, Xue L, Hu D, Cui F, Liang X. Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China. *J Viral Hepat.* 2016; 23(3): 202-10.
44. Kang G, Ma F, Chen H, Yang Y, Guo S, Wang Z, Liang X, Li L, Cui F, Zhang L. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers. *Vaccine.* 2015; 33(33): 4093-9.
45. Chen YS, Zheng H, Liu YM, Wang FZ, Wu ZH, Miao N, Sun XJ, Zhang GM, Cui FQ, Liang XF. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013. *Hum Vaccin Immunother.* 2016 Feb 18:1-9. [Epub ahead of print] No abstract available. PMID: 26891075
46. Wang HB, Yu WZ, Wang XQ, Wushouer F, Wang JP, Wang DY, Cui FQ, Zheng JS, Wen N, Ji YX, Fan CX, Wang HL, Ning GJ, Huang GH, Yan DM, Su QR, Liu DW, Zhang GM, Reilly KH, Ning J, Fu JP, Mi SS, Luo HM, Yang WZ. An outbreak following importation of wild

- poliovirus in Xinjiang Uyghur Autonomous Region, China, 2011. *BMC Infect Dis.* 2015 Jan 31;15:34. doi: 10.1186/s12879-015-0761-y. PMID: 25636581
47. Wen N, Fan CX, Fu JP, Ning J, Ji YX, Luo HM, Wang HQ, Zhu SL, Yu WZ, Wang HB, Zhu H, **Cui FQ**, Li DX, Wang SW, Xu WB, Hao LX, Cao LS, Luo L, Han L, Cao L, Xia W, Wang XQ, Reilly KH, Wushouer F, Mi SS, Yang WZ, Li L. Enhanced surveillance of acute flaccid paralysis following importation of wild poliovirus in Xinjiang Uygur Autonomous Region, China. *BMC Infect Dis.* 2014 Feb 27;14:113. doi: 10.1186/1471-2334-14-113. PMID:
 48. Liang P, Zu J, Yin J, Li H, Gao L, **Cui F**, Wang F, Liang X, Zhuang G. The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China, 1992-2006: A mathematical model analysis. *Journal of theoretical biology*, 2015, 386: 115-121.
 49. Zhang L, Liu J, Lu J, Yan B, Song L, Li L, **Cui F**, Zhang G, Wang F, Liang X, Xu A. Antibody response to revaccination among adult non-responders to primary Hepatitis B vaccination in China. *Human Vaccines & Immunotherapeutics*, 2015, 11(11): 2716-2722.
 50. Kang G, Ma F, Chen H, Yang Y, Guo S, Wang Z, Liang X, Li L, **Cui F**, Zhang L. Efficacy of antigen dosage on the hepatitis B vaccine response in infants born to hepatitis B-uninfected and hepatitis B-infected mothers. *Vaccine.* 2015 Aug 7;33(33):4093-9. doi: 10.1016/j.vaccine.2015.06.081. Epub 2015 Jul 3. PMID: 26144895
 51. Xiao M, Qiu Q, Pang X, Liang X, Li L, **Cui F**, Wang F, Zhang G, Li H, Wang L, Zhang W. Immune response in infants after universal high-dose hepatitis B vaccination: A community-based study in Beijing, China. *Vaccine*, 2015, 33(43): 5878-5883. doi: 10.1016/j.vaccine.2015.06.018. [Epub ahead of print] PMID: 26117148
 52. Yin J, Ji Z, Liang P, Wu Q, **Cui F**, Wang F, Liang X, Zhuang G. The doses of 10 µg should replace the doses of 5 µg in newborn hepatitis B vaccination in China: A cost-effectiveness analysis. *Vaccine.* 2015 Jul 17;33(31):3731-8. doi: 10.1016/j.vaccine.2015.05.082. Epub 2015 Jun 6. PMID: 26057138
 53. Wang F, Shen L, **Cui F**, Zhang S, Zheng H, Zhang Y, Liang X, Wang F, Bi S. The long-term efficacy, 13-23 years, of a plasma-derived hepatitis B vaccine in highly endemic areas in China. *Vaccine.* 2015 May 28;33(23):2704-9. doi: 10.1016/j.vaccine.2015.03.064. Epub 2015 Apr 2. PMID:25843269
 54. 缪宁, 张国民, 郑徽, 吴振华, 孙校金, 王锋, 王富珍, **崔富强**, 李黎. 2013年中国乙型肝炎监测点数据分析, 中华预防医学杂志 2015, 49(9):766-769.
 55. 张丽, 吕静静, 颜丙玉, 刘甲野, 冯艺, 陈士玉, 周立波, 梁晓峰, **崔富强**, 王富珍, 徐爱强. 乙型肝炎疫苗初次免疫成年无应答者再次免疫后24个月免疫持久性观察, 中华预防医学杂志 2015, 49(9):782-787.

2014年

56. 余文周,岳晨妍,周玉清,张旋,**崔富强**,王华庆,李黎. 中国2013年免疫规划宣传活动分析[J]. 中国疫苗和免疫,2014,(4): 289-293.
YU Wen-zhou;YUE Chen-yan;ZHOU Yu-qing; Health Education and Promotion Campaigns on National Expanded Program for Immunization in 2013[J]. *Chinese Journal of Vaccines and Immunization*,2014,20(4):289-293.
57. 郑徽,王富珍,庄贵华,张国民,陈园生,龚晓红,**崔富强**,梁晓峰. 基于社区人群的乙型肝炎病毒慢性感染者生存质量多中心调查[J]. 中国疫苗和免疫,2014,(4) :309-343.
ZHENG Hui;WANG Fu-zhen;ZHUANG Gui-hua; Quality of Life among Chronic Hepatitis B

- Virus Infected People in their Communities[J]. Chinese Journal of Vaccines and Immunization, 2014,20(4):309-343.
58. 余文周,李放军,张振国,单芙蓉,刘波,苏琪茹,颜洁,周玉清,孙丽,李克莉,刘刚,安志杰,许涤沙,段梦娟,张旋,褚尧竹,崔富强,王华庆,李黎. 2013 年媒体报道乙型肝炎疫苗事件后部分省儿童家长对预防接种信任度的调查分析[J]. 中国疫苗和免疫,2014,(3) :233-236.
YU Wen-zhou;LI Fang-jun;ZHANG Zhen-guo. Analysis of Parental Confidence on Vaccination after the Hepatitis B Vaccine Event Reported by the Media in 2013 in Some Provinces[J]. Chinese Journal of Vaccines and Immunization, 2014,20(3):233-236.
59. 苏琪茹,徐爱强,Peter Strebel,许文波,郝利新,周勇,李慧,庞星火,马超,张燕,方刚,崔富强,丁峥嵘,沈永刚,安志杰,张永基,谢淑云,William Schluter,余文周,郑景山,夏伟,王青,郑慧贞,张延炆,张丽杰,段梦娟,杨维中,Lance Rodewald,李黎,罗会明. 中国消除麻疹的关键技术问题:专家解读共识[J]. 中国疫苗和免疫,2014,(3) :264-283.
SU Qi-ru;XU Ai-qiang;Peter Strebel; National and International Experts' Consensus on Key Technical Issues of Measles Elimination in China[J]. Chinese Journal of Vaccines and Immunization, 2014,20(3):264-283.
60. 岳晨妍,周玉清,张旋,朱徐,顿珠多吉,杜雯,张晓曙,关炳菊,甫尔哈提·吾守尔,崔富强. 中国西部贫困地区儿童监护人预防接种知识调查及首剂麻疹减毒活疫苗及时接种的影响因素分析[J]. 中国疫苗和免疫,2014,(2) :109-154.
YUE Chen-yan;ZHOU Yu-qing;ZHANG Xuan; Survey on the Children Guardians' Vaccination Knowledge Status and Analysis on Influencing Factors of Timely First Dose of Measles Attenuated Live Vaccine Vaccination in Western Poverty Area of China[J]. Chinese Journal of Vaccines and Immunization, 2014,20(2):109-154.
61. 解瑞峰,张栋梁,王鸿,殷大鹏,郑景山,刘青恋,郝利新,余文周,温宁,张国民,李艺星,刘大卫,夏伟,刘燕敏,刘宇,漆琪,朱锦蓉,杨慎宗,张琴,王华庆,崔富强,罗会明,方刚,李黎. 芦山地震灾区疫苗可预防传染病的初步风险评估[J]. 中国疫苗和免疫,2014,(2) :160-164.
XIE Rui-feng;ZHANG Dong-liang;WANG Hong; Preliminary Assessment on Risk of Vaccine Preventable Diseases in Earthquake Area in Lushan,Sichuan Province[J]. Chinese Journal of Vaccines and Immunization, 2014,20(2):160-164.
62. 岳晨妍,孙校金,韦宁,郭立春,郝增平,赵金华,崔哲哲,肖林,朱晓磊,莫想换,余文周,施国庆,安志杰,崔富强,王华庆,李黎. 2013 年媒体报道接种乙型肝炎疫苗事件对儿童家长影响的快速调查[J]. 中国疫苗和免疫,2014,(2) :100-104+192.
YUE Chen-yan;SUN Xiao-jin;WEI Ning; Quick Assessment on the Influence of Hepatitis B Vaccine Event Reported by Media to Children's Parents in 2013[J]. Chinese Journal of Vaccines and Immunization, 2014,20(2):100-104+192.
63. 郑徽,杜飞,陈筱纯,王富珍,张国民,陈园生,缪宁,孙校金,崔富强. 四川地震灾区甲型肝炎疫苗群体性预防接种后四年保护效果分析[J]. 中国疫苗和免疫,2014,(1):40-44.
ZHENG Hui;DU Fei;CHEN Xiao-chun; Evaluation on Four Years' Protective Effects after Hepatitis A Mass Campaign in the Earthquake Areas in Sichuan Province,China[J]. Chinese Journal of Vaccines and Immunization, 2014,20(1):40-44.
64. 黎健,任宏,徐爱强,张丽,翟祥军,李艳萍,颜丙玉,朱凤才,黄腾,崔富强,梁晓峰,李燕婷. 新生儿 5 微克重组乙型肝炎疫苗(酿酒酵母)无应答者不同剂次和剂量再免疫血清学效果研究[J]. 中国疫苗和免疫,2014,(1) :31-35.
LI Jian;REN Hong;XU Ai-qiang; Study of Response to Revaccination of Hepatitis B Vaccine (HepB) with Different Schedule and Different Doses for Non-response Infants after Primary

Immunization with 5 μ g HepB Made by Recombinant Deoxyribonucleic Acid Techniques in *Saccharomyces Cerevisiae*[J]. *Chinese Journal of Vaccines and Immunization*, 2014,20(1):31-35.

65. Yan B, Lyu J, Liu J, Feng Y, Xu A, Chen S, Zhou L, Liang X, **Cui F**, Wang F, Zhang L. [Antibody persistence following booster vaccination with three doses of hepatitis B vaccines among low-response adults in Zhangqiu county of Shandong province: 24-month of follow-up from 2009]. *Zhonghua Yu Fang Yi Xue Za Zhi*. 2014 Dec;48(12):1043-7. Chinese. PMID:25619213, 2014, (12): 1043-1047.
66. 颜丙玉, 吕静静, 刘甲野, 等. 成年人乙型肝炎疫苗低应答者加强免疫后 24 个月免疫持久性研究[J]. *中华预防医学杂志*, 2014 (012): 1043-1047.
67. Jia Y, Li L, **Cui F**, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N, Sun X, Zhang L, Lv J, Yang F. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China. *Hum Vaccin Immunother*. 2014;10(10):2983-91. doi: 10.4161/hv.29944. PMID:25483678
68. Shen L, Yin W, Zheng H, Cui F, Zhang S, Wang F, Wang F, Zhang Y, Liang X, Bi S. Molecular epidemiological study of hepatitis B virus genotypes in Southwest, China. *J Med Virol*. 2014 Aug;86(8):1307-13. doi: 10.1002/jmv.23965. Epub 2014 May 5. PMID: 24797477

2013 年

69. 贾元熙, 崔富强, 张栋梁, 张国民, 龚晓红, 王富珍, 郑徽, 吴振华, 缪宁, 孙校金, 张丽, 吕静静, 杨峰, 梁晓峰, 李黎. 欧洲多维水平量表在中国慢性乙型肝炎病毒感染者中的适用性调查. *中国疫苗和免疫*,2013,19(6):492-497.
70. 马福宝, 梁晓峰, 张龙华, 康国栋, 阎邵红, 郭邵红, 崔富强, 董春明,李黎, 陈海平, 杨云凯. 新生儿及以上人群接种不同剂量重组乙型肝炎疫苗(酿酒酵母)的免疫学效果观察分析. *中国疫苗和免疫*,2013,19(6):485-491.
71. 徐也晴, 崔富强,罗会明, 裴迎新,马会来. 北京市主要公交线路车站点健康公益广告发布现状调查. *中华流行病学杂志*,2013,34(12):1266.
72. Xu Y, Cui F, Luo H, Pei Y, Ma H. Current situation on health education billboard set at bus stops of main roads in Beijing. *Chin J Epidemiol*, 2013,34(12):1266.
73. Kane M.A. Hadler S.C, Lee L, Shapiro C.N, Cui F, Wang X, Kumar R. The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization. *Vaccine* 31S (2013) J15– J20. (执笔作者)
74. Xiaofeng Liang, Shengli Bi, Weizhong Yang, Long Wang, Gang Cui, Fuqiang Cui, Yong Zhang, Jianhua Liu, Xiaohong Gong, Yuansheng Chen, Fuzhen Wang, Hui Zheng, Feng Wang, Jing Guo, Zhiyuan Jia, Jingchen Ma, Huaqing Wang, Huiming Luo, Li Li, Shuigao Jin, Stephen C. Hadler, Yu Wang. Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccination. *Vaccine* 31S (2013) J21– J28. (执笔作者)
75. Yvan Hutin, Karen Hennessey, Lisa Cairns, Yongji Zhang, Hui Li, Lianfei Zhao, Fuqiang Cui, Lisa Lee, Vivian Tan, Yoshihiro Takashima, Shuyan Zuo, Stephen Hadler. Improving hepatitis B vaccine timely birth dose coverage: Lessons from five demonstration projects in China, 2005–2009. *Vaccine* 31S (2013) J49– J55.
76. Stephen C. Hadler, Cui Fuqiang, Francisco Averhoff, Thomas Taylor, Wang Fuzhen, Li Li, Liang Xiaofeng, Yang Weizhong. The impact of hepatitis B vaccine in China and in the China GAVI Project. *Vaccine* 31S (2013) J66– J72.

77. Zhang L, Peng Z, Ou J, Zeng G, Fontaine R, Liu M, Cui F, Hong R, Zhou H, Huai Y, Chuang SK, Leung YH, Feng Y, Luo Y, Shen T, Zhu BP, Widdowson MA, Yu H. Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft, 2009. *Emerging Infectious Diseases*, 2013, 19(9):1403-1409.
78. 沈立萍, 龚晓红, 王锋, 张爽, 崔富强, 王富珍, 尹文娇, 张勇, 梁晓峰. 乙型肝炎疫苗长期免疫效果评价及免疫持久性研究. *中华微生物学和免疫学杂志*, 2013, 33(1): 6-10.
79. Shen L, Gong X, Wang F, Zhang S, Cui F, Wang F, Yin W, Zhang Y, Liang X. Study on long term efficacy and duration of hepatitis B vaccine in China. *Chin J Microbiol Immunol* 2013, 33(1):6-10.
80. 温宁, 罗会明, 汪海波, 崔富强, 郑徽, 王富珍, 张颖, 樊春祥, 郝利新, 马超, 刘波. 2011 年新疆维吾尔自治区发生输入脊髓灰质炎疫情后对各省(自治区、直辖市)输入传播风险评估及应对的研究. *中国疫苗和免疫*, 2013, 19(3):193-198.
Wen N, Luo H, Wang H, Cui F, Zheng H, Wang F, Zhang Y, Fan C, Hao L, Ma C, Liu B. Study on Risk Assessment and Response of Wild Poliovirus Importation after Polio Imported into Xinjiang Uygur Autonomous Region. *Chinese Journal of Vaccines and Immunization*, 2013, 19(3) :193-198.
81. 张丽, 颜丙玉, 吕静静, 刘甲野, 冯艺, 徐爱强, 龚晓红, 崔富强, 梁晓峰, 李波, 陈德颖, 吉秀兰, 陈士玉, 新生儿 5 微克重组乙型肝炎疫苗(酿酒酵母)初次免疫低应答者不同种类、剂量和剂次乙型肝炎疫苗再免疫的血清学效果分析. *中国疫苗和免疫*, 2013, 19(3):250-254.
Zhang L, Yan B, Lv J, Liu J, Feng Y, Xu A, Gong X, Cui F, Liang X, Li B, Chen D, Ji X, Chen S. Assessment on Serological Survey of Antibody to Hepatitis B Virus Surface Antigen Response to Revaccination of 5 μ g Recombinant Hepatitis B Vaccine Derived from Yeast with Different Type, Different Dosage and Different Schedule among Low-response Infants after primary vaccination. *Chinese Journal of Vaccines and Immunization*, 2013, 19(3) :250-254.
82. 孙爱武, 王锋, 王富珍, 张爽, 涂秋风, 邵晓萍, 郑徽, 孙校金, 龚晓红, 缪宁, 崔富强, 毕胜利, 陈园生, 乙型肝炎病毒表面抗原携带者主动告知配偶的可行性研究. *中国疫苗和免疫*, 2013, 19(3):260-265.
Sun A, Wang F, Wang F, Zhang S, Tu Q, Shao X, Zheng H, Sun X, Gong X, Miao N, Cui F, Bi S, Chen Y. The Feasible Study of Hepatitis B Virus Surface Antigen Carriers Initiative Inform the Hepatitis B Virus Infection to the Spouse. *Chinese Journal of Vaccines and Immunization*, 2013, 19(3) : 260-265.
83. 缪宁, 金龙洙, 朴红心, 陈龙男, 王富珍, 陈园生, 郑徽, 吴振华, 崔富强, 李黎, 梁晓峰, 延边朝鲜族自治州丙型肝炎病毒感染危险因素研究. *中国疫苗和免疫*, 2013, 19(2): 159-163.
Miao N, Jin L, Piao H, Chen L, Wang F, Chen Y, Zheng H, Wu Z, Cui F, Li L, Liang X. Study on Risk Factors of Hepatitis C Virus Infection in Yanbian Korean Prefecture. *Chinese Journal of Vaccines and Immunization*, 2013, 19(2) :159-163.
84. 张颖, 罗会明, 温宁, 崔富强, 汪海波. 脊髓灰质炎野病毒输入传播风险评估工具的研究. *中国疫苗和免疫*, 2013, 19(1):17-19.
Zhang Y, Luo H, Wen N, Cui F, Wang H. A Study of Risk Assessment Tool on Wild Poliovirus Importation and Transmission. *Chinese Journal of Vaccines and Immunization*, 2013, 19(1) :17-19.
85. Luo HM, Zhang Y, Wang XQ, Yu WZ, Wen N, Yan DM, Wang HQ, Wushouer F, Wang HB, Xu

AQ, Zheng JS, Li DX, Cui H, Wang JP, Zhu SL, Feng ZJ, Cui FQ, Ning J, Hao LX, Fan CX, Ning GJ, Yu HJ, Wang SW, Liu DW, Wang DY, Fu JP, Gou AL, Zhang GM, Huang GH, Chen YS, Mi SS, Liu YM, Yin DP, Zhu H, Fan XC, Li XL, Li KL, Tang HS, Xu WB, Wang Y, Yang WZ. Identification and Control of a Poliomyelitis Outbreak in Xijiang, China. *The New England Journal of Medicine*, 2013, 36(21).

86. Zhang L, Peng Z, Ou J, Zeng G, Fontaine R, Liu M, Cui F, Hong R, Zhou H, Huai Y, Chuang SK, Leung YH, Feng Y, Luo Y, Shen T, Zhu BP, Widdowson MA, Yu H. Protection by Face Masks against Influenza A(H1N1)pdm09 Virus on Trans-Pacific Passenger Aircraft, 2009. *Emerging Infectious Diseases*, 2013, 19(9):1403-1409.

2012 年

87. 冯艺, 颜丙玉, 张丽, 吕静静, 刘甲野, 龚晓红, 崔富强, 梁晓峰, 陈士玉, 徐爱强. 成年人乙型肝炎疫苗初次免疫低应答者加强免疫效果分析. *中华预防医学杂志*, 2012, 46(9): 2012, 46(9): 813-818.

Feng Y, Yan B, Lv J, Liu J, Gong X, Cui F, Liang X, Chen S, Xu A. Study on antibody response to revaccination of hepatitis B vaccine among firstly low-response adults. *Chin J Prev Med*, 2012, 46(9): 813-818.

88. 梁晓峰, 崔富强. 中国成人乙型肝炎免疫预防技术指南. *胃肠病学和肝病学杂志*, 2012, 21(3): 197-201.

Liang X, Cui F. Technical guide for adult hepatitis B immunization in China. *Chinese Journal of Gastroenterology and Hepatology*, 2012, 21(3): 197-201.

89. 颜丙玉, 张丽, 吕静静, 刘甲野, 冯艺, 纪峰, 徐爱强, 陈士玉, 龚晓红, 崔富强, 梁晓峰. 成人重组酿酒酵母和汉逊酵母乙型肝炎疫苗免疫应答及相关因素研究. *中华流行病学杂志*, 2012, 33(9): 988-989.

Yan B, Zhang L, Lv J, Liu J, Feng Y, Ji F, Xu A, Chen S, Gong X, Cui F, Liang X. Comparison of the antibody response and related influencing factors after primary immunization by 10 μ g hepatitis B vaccine made from recombinant DNA techniques in *Saccharomyces* and *Hansenula polymorpha* among adults. *Chin J Epidemiol*, 2012, 33(9): 988-989.

90. 张丽, 张卫, 翟祥军, 李艳萍, 黎健, 颜丙玉, 李燕婷, 朱凤才, 黄腾, 李立秋, 龚晓红, 崔富强, 梁晓峰, 徐爱强. 新生儿 5 μ g 和 10 μ g 重组酵母乙型肝炎疫苗初免后抗体免疫应答比较. *中华流行病学杂志*, 2012, 33(3): 305-308.

Zhang L, Zhang W, Zhai X, Li Y, Li J, Yan B, Li Y, Zhu F, Huang T, Li L, Gong X, Cui F, Liang X, Xu A. Comparison on the antibody response after primary immunization of 5 μ g and 10 μ g hepatitis B vaccine made by recombinant DNA techniques among newborns. *Chin J Epidemiol*, 2012, 33(3): 305-308.

91. 张丽, 翟祥军, 李艳萍, 张卫, 朱凤才, 黄腾, 颜丙玉, 刘甲野, 李立秋, 龚晓红, 崔富强, 梁晓峰, 徐爱强. 中国 4 省(区市)早产儿和足月儿乙型肝炎疫苗免疫应答多中心比较研究. *中华流行病学杂志*, 2012, 33(2): 185-190.

Zhang L, Zhai X, Li Y, Li J, Yan B, Li Y, Zhu F, Huang T, Li L, Gong X, Cui F, Liang X, Xu A. Multi-center matching study on antibody response between preterm and full term infants after primary immunization of hepatitis B vaccine. *Chin J Epidemiol*, 2012, 33(2): 185-190.

92. 陈永弟, 梁晓峰, 姚军, 崔富强, 王富珍, 沈灵智. 5 岁以上儿童 5 μ g 重组乙型肝炎疫苗(酵母)加强免疫效果评价. *中国预防医学杂志*, 2012, 13(2): 84-87.

Chen Y, Liang X, Yao J, Cui F, Wang F, Shen L. Evaluation on booster immunization efficacy

- of 5 µg hepatitis B vaccine made by recombinant deoxyribonucleic acid(DNA) techniques in polymorpha yeast of variant dosage in children aged over 5 years old. *Chin Prev Med*, 2012,13(2):81-87.
93. 陈永弟,姚军,梁晓峰,崔富强,王富珍,沈灵智.儿童甲乙型肝炎联合疫苗加强免疫效果评价. *中国预防医学杂志*,2012,13(4):256-259.
Chen Y, Yao J, Liang X, Cui F, Wang F, Shen L. Evaluation on booster immunization efficacy of hepatitis A and B combined vaccine of one dosage in children. *Chin Prev Med*, 2012,13(4):256-259.
94. 杜雯,周玉清,岳晨妍,夏伟,樊春祥,崔富强,梁晓峰.西部地区预防接种人际传播策略干预效果评价. *中国健康教育*,2012,28(8):632-634.
Du W, Zhou Y, Yue C, Xia W, Fan C, Cui F, Liang X. Intervention effect evaluation of interpersonal communication for immunization health education in western areas. *Chinese Journal of Health Education*, 2012,28(8):632-634.
95. 吕静静,颜丙玉,张丽,刘甲野,冯艺,徐爱强,龚晓红,崔富强,梁晓峰,姜梅,陈德颖,吉秀兰,陈士玉.新生儿接种 5 微克重组乙型肝炎疫苗(酿酒酵母)的免疫应答及其影响因素研究. *中国疫苗和免疫*, 2012,18(4):320-324.
Lv J, Yan B, Zhang L, Liu J, Feng Y, Xu A, Gong X, Cui F, Liang X, Jiang M, Chen D, Ji X, Chen S. Study on the Immune Response and Influencing Factors of Primary Immunization by 5µg Hepatitis B Vaccine Made by Recombinant Dexyribonucleic Acid Techniques in *Saccharomyces Cerevisiae* Yeast among Infants. *Chinese Journal of Vaccines and Immunization*, 2012,18(4):320-324.
96. 尹文娇,王锋,沈立萍,王晓艳,张爽,陈园生,崔富强,毕胜利,张勇.乙型肝炎病毒脱氧核糖核酸载量与乙型肝炎病毒 e 抗原和抗体定量对数正相关. *中国疫苗和免疫*,2012,18(4):316-319.
Yin W, Wang F, Shen L, Wang X, Zhang S, Chen Y, Cui F, Bi S, Zhang Y. The Positive Correlation of Log Hepatitis B Virus (HBV) Deoxyribonucleic Acid Load and Log HBV e Antigen (HBeAg) and Log Antibody to HBeAg. *Chinese Journal of Vaccines and Immunization*, 2012,18(4):316-319.
97. 王富珍,龚晓红,崔富强,陈园生,郑徽,吴振华,李黎,罗会明,梁晓峰.全国 1~14 岁人群乙型肝炎病毒表面抗原阳性危险因素分析. *中国疫苗和免疫*,2012,18(2):118-122.
Wang F, Gong X, Cui F, Chen Y, Zheng H, Wu Z, Li L, Luo H, Liang X. Analysis on risk factors of hepatitis B virus surface antigen prevalence among people aged 1-14 years in China. *Chinese Journal of Vaccines and Immunization*, 2012,18(2):118-122.
98. 孙校金,崔富强,龚晓红,王富珍,陈园生,郑徽,吴振华,缪宁,马汉平,罗梅,余文,速存芬,钱晏飞,杨政,莫峰,罗会明,梁晓峰.富源县阻断乙型肝炎病毒母婴传播的现况调查. *中国疫苗和免疫* 2012,18(1):31-36.
Sun X, Cui F, Gong X, Wang F, Chen Y, Zheng H, Wu Z, Miao N, Ma H, Luo M, Yu W, Su C, Qian Y, Yang Z, Mo F, Luo H, Liang X. Survey on preventing perinatal transmission of hepatitis B virus in Fuyuan county. *Chinese Journal of Vaccines and Immunization*, 2012,18(1):31-36.
99. 郑徽,王富珍,陈园生,崔富强,龚晓红,吴振华,缪宁,罗会明,梁晓峰.中国东中西部地区 1~14 岁儿童乙型病毒性肝炎流行现状及乙型肝炎疫苗接种情况. *中国疫苗和免疫*,2012,18(1):19-25.
Zheng H, Wang F, Chen Y, Cui F, Gong X, Wu Z, Miao N, Luo H, Liang X. The Hepatitis B Prevalence and the Vaccination Statutes of the 1-14 Years-old Children in Eastern, Central and

- Western Areas of China. Chinese Journal of Vaccines and Immunization. 2012,18(1):19-25.
100. 陈园生,王富珍,郑徽,崔富强,龚晓红,吴振华,缪宁,罗会明,梁晓峰.我国六个区域 2006 年 1~59 岁人群乙型肝炎病毒感染现状及疫苗接种情况分析.中国疫苗和免疫,2012,18(1):14-18.
- Chen Y, Wang F, Zheng H, Cui F, Gong X, Wu Z, Miao N, Luo H, Liang X. The seroepidemiological study and vaccination status analysis on viral hepatitis B among population aged 1-59 years in six areas of China in 2006. Chinese Journal of Vaccines and Immunization. 2012,18(1):14-18.
101. 沈立萍,张爽,王锋,张勇,张文英,余陶,王富珍,崔富强,梁晓峰,毕胜利.重组乙型肝炎疫苗(酿酒酵母)免疫 12 年保护效果及持久性分析.中国疫苗和免疫,2012,18(1):1-5.
- Shen L, Zhang S, Wang F, Zhang Y, Zhang W, Yu T, Wang F, Cui F, Liang X, Bi S. Study on Effect and Duration of Hepatitis B Vaccine Made by Deoxyribonucleic Acid Techniques with Saccharomyces Cerevisiae Yeast after Long-term Vaccination. Chinese Journal of Vaccines and Immunization. 2012,18(1):1-5.
102. 吕静静,颜丙玉,陈士玉,徐爱强,刘甲野,冯艺,龚晓红,崔富强,梁晓峰,张丽,王健.成人乙型肝炎疫苗初免低应答后加强免疫及影响因素分析.山东大学学报(医学版),2012,50(11):126-132.
- Lv J, Yan B, Chen S, Xu A, Liu J, Feng Y, Gong X, Cui F, Liang X, Zhang L, Wang J. Antibody response and the influencing factors after revaccination with three doses of hepatitis B vaccines among low-response adults. Journal of Shandong University(Health Sciences), 2012,50(11):126-132.
103. Liang X, Cui F. Technical guide for adult hepatitis B immunization in China. Chinese Journal of Gastroenterology and Hepatology, 2012,21(3):197-201.

2011 年

104. 陈永弟,梁晓峰,姚军,崔富强,王富珍,沈灵智,方春福,陈荣富,刘灿磊,郑小华.高及中流行区儿童血源乙型肝炎疫苗接种 11~14 年免疫效果评价.中华预防医学杂志,2011,45(6):562-564.
- Chen Y, Liang X, Yao J, Cui F, Wang F, Shen L, Fang C, Chen R, Liu C, Zheng X. Evaluation on the immunology of plasma derived hepatitis B vaccine 11 to 14 years later among children in high and middle epidemic areas. Chin J Prev M, 2011,45(6):562-564.
105. 陈永弟,梁晓峰,姚军,崔富强,王富珍,沈灵智,严传富,郑小华.不同剂次重组乙型肝炎疫苗(中国仓鼠卵巢细胞)加强免疫效果评价.中华微生物学和免疫学杂志,2011,31(7):657-658.
- Chen Y, Liang X, Yao J, Cui F, Wang F, Shen L, Yan C, Zheng X. Evaluation on booster immunization efficacy of recombinant hepatitis B vaccine made by recombinant Deoxyribonucleic Acid Techniques in Chinese Hamster Ovary by different dosage in children. Chin J Microbiol Immunol, 2011,31(7): 657-658.
106. 刘甲野,颜丙玉,张丽,徐爱强,吕静静,冯艺,龚晓红,崔富强,梁晓峰,李波,陈德颖,吉秀兰,陈士玉.早产儿和足月儿乙型肝炎疫苗初次免疫和再次免疫抗体应答配对分析.中华流行病学杂志,2011,32(10):1055-1056.
- Liu J, Yan B, Zhang L, Xu A, Lv J, Feng Y, Gong X, Cui F, Liang X, Li B, Chen D, Ji X, Chen S. Matching study on antibody response between preterm and full-term infants after primary immunization and revaccination of hepatitis B. Chin J Epidemiol, 2011,32(10):1055-1056.
107. 陈园生,李黎,崔富强,邢文革,王璐,贾志远,周脉耕,龚晓红,王富珍,郑徽,罗会明,毕胜利,汪

- 宁,杨维中,梁晓峰. 中国丙型肝炎血清流行病学研究.中华流行病学杂志,2011,32(9):888-891.
- Chen Y, Li L, Cui F, Xing W, Wang L, Jia Z, Zhou M, Gong X, Wang F, Zheng H, Luo H, Bi S, Wang N, Yang W, Liang X. A sero-epidemiological study on hepatitis C in China. *Chin J Epidemiol*, 2011,32(9):888-891.
108. 马起山,邹宇华,张顺祥,梁森,肖和卫,谢旭,梅树江,贾卫东,张宇锋,崔富强,王富珍,梁晓峰. 广州市乙型肝炎相关疾病住院病例无形费用及其影响因素分析.中华流行病学杂志,2011,32(8):764-767.
- Ma Q, Zou Y, Zhang X, Liang S, Xiao H, Xie X, Mei S, Jia W, Zhang Y, Cui F, Wang F, Liang X. Estimation on the intangible cost and influencing factors for patients with hepatitis B-related diseases. *Chin J Epidemiol*, 2011,32(8): 764-767.
109. 陈永弟,梁晓峰,姚军,崔富强,李倩,蒋征刚,王富珍,方春福,陈荣富,苏美芳,郑小华.2789 例 10 岁以上儿童重组乙型肝炎疫苗加强免疫效果评价.中华流行病学杂志, 2011,32(3):252-255.
- Chen Y, Liang X, Yao J, Cui F, Li Q, Jiang Z, Wang F, Fang C, Chen Y, Su M, Zheng X. Evaluation on the efficacy of recombinant hepatitis B vaccine booster immunization in 2789 children aged over 10 years. *Chin J Epidemiol*, 2011,32(3):252-255.
110. 马起山,邹宇华,张顺祥,梁森,肖和卫,谢旭,梅树江,贾卫东,张宇锋,崔富强,王富珍,梁晓峰. 广州市乙型肝炎相关疾病直接经济负担及其影响因素分析.中国预防医学杂志 2011,12(5):383-386.
- Ma Q, Zou Y, Zhang X, Liang S, Xiao H, Xie X, Mei S, Jia W, Zhang Y, Cui F, Wang F, Liang X. Analysis on the direct economic burden and influence factors of HBV-related diseases in Guangzhou. *Chin P Med*, 2011, 12(5):383-386.
111. 梁森,张顺祥,马起山,肖和卫,谢旭,梅树江,胡东生,周博平,李兵,崔富强,王富珍,梁晓峰.深圳市乙肝住院病人年直接经济负担及对家庭经济影响分析.中国卫生经济, 2011,30(2):56-58.
- Liang S, Zhang S, Ma Q, Xiao H, Xie X, Mei S, Hu D, Zhou B, Li B, Cui F, Wang F, Liang X. Study on the direct economic burden of hepatitis B and its economic impact on family in Shenzhen city. *Chinese Health Economics*, 2011,30(2):56-58.
112. 孙校金,崔富强,王富珍,陈园生,郑徽,吴振华,缪宁,马汉平,罗梅,余文,速存芬,钱晏飞,杨政,莫峰,梁晓峰.贫困地区孕产妇乙型肝炎病毒表面抗原筛查服务利用现状及影响因素研究.中国疫苗和免疫,2011,17(5):408-435.
- Sun X, Cui F, Wang F, Chen Y, Zheng H, Wu Z, Miao N, Luo M, Yu W, Su C, Qian Y, Yang Z, Mo F, Liang X. Application and influences of prenatal screening for hepatitis B virus surface antigen among pregnant women in poverty areas. *Chinese Journal of Vaccines and Immunization*. 2011,17(5):408-435.
113. 张丽,颜丙玉,吕静静,刘甲野,冯艺,徐爱强,龚晓红,崔富强,梁晓峰,姜梅,陈德颖,吉秀兰,陈士玉.新生儿5微克重组乙型肝炎疫苗(酿酒酵母)初次免疫无应答者不同剂量和剂次再免疫效果分析.中国疫苗和免疫,2011,17(5):395-398.
- Zhang L, Yan B, Lv J, Liu J, Feng Y, Xu A, Gong X, Cui F, Liang X, Jiang M, Chen D, Ji X, Chen S. Response to revaccination of hepatitis B vaccine(HepB) with different doses and different schedule among non-response infants after 3 doses of 5 μ g HepB made by recombinant Deoxyribonucleic Acid techniques in *Saccharomyces Cerevisiae* yeast primary vaccination. *Chinese Journal of Vaccines and Immunization*. 2011,17(5): 395-398.

114. 姚军,梁晓峰,陈永弟,崔富强,蒋征刚,李倩,王富珍,沈灵智,方春福,陈荣富.乙型肝炎病毒高流行区儿童接种乙型肝炎疫苗 5~16 年免疫效果评价.中国疫苗和免疫, 2011,17(4):294-298.
Yao J, Liang X, Chen Y, Cui F, Jiang Z, Li Q, Wang F, Shen L, Fang C, Chen R. Evaluation on Immune effect of hepatitis B vaccine Immunization among children aged 5-16 years in high epidemic areas of hepatitis B virus. Chinese Journal of Vaccines and Immunization. 2011, 17(4):294-298.
115. 孙校金,崔富强,龚晓红,陈园生,王富珍,郑徽,吴振华,缪宁,梁晓峰.阻断乙型肝炎病毒母婴传播的研究进展.江苏预防医学,2011,22(5):66-70.
Sun X, Cui F, Gong X, Chen Y, Wang F, Zheng H, Wu Z, Miao N, Liang X. Progress towards preventing perinatal transmission of HBV. Jiangsu J Prev Med,2011,22(5):66-70.
116. 沈灵智,陈永弟,蒋征刚,李倩,陈恩富,梁晓峰,崔富强,姚军.不同剂次重组乙型病毒性肝炎疫苗(汉逊酵母)加强免疫效果研究.疾病监测,2011,26(10):811-814.
Shen L, Chen Y, Jiang Z, Li Q, Chen E, Liang X, Cui F, Yao J. Evaluation on booster immunization efficacy of 10 μ g recombinant hepatitis B vaccine made by recombinant Deoxyribonucleic Acid Techniques in Hansenula Polymorpha Yeast by different dosage in children. Disease Surveillance, 2011,26(10):811-814.

2010 年

117. Yin J, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, **Cui F**, Liang X, Schaefer S, Cao G. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev. 2010,19(3):777-86.
尹建华,张宏伟,何永超,谢佳欣,刘世健,常文君,谭晓杰,顾春英,陆伟,汪洪洋,毕胜利,**崔富强**,梁晓峰,Stephan Schaefer,曹广文. Cancer Epidemiol Biomarkers Prev. 2010,19(3):777-86.
118. 梁森,张顺祥,马起山,肖和卫,吕秋莹,谢旭,梅树江,胡东生,周伯平,李兵,陈敬芳,**崔富强**,王富珍,梁晓峰.深圳市乙型肝炎相关疾病经济负担及其影响因素分析.中华流行病学杂志, 2010,31(12): 1340-1345.
Liang S, Zhang S, Ma Q, Xiao H, Lv Q, Xie X, Mei S, Hu D, Zhou B, Li B, Chen J, **Cui F**, Wang F, Liang X. Financial burden of hepatitis B-related diseases and factors influencing the costs in Shenzhen, China. Chin J Epidemiol, 2010,31(12): 1340-1345.
119. 郑徽,**崔富强**,龚晓红,王富珍,陈园生,吴振华,王华庆,李黎,罗会明,梁晓峰.我国育龄期妇女乙型肝炎病毒表面抗原及 e 抗原流行现状分析.中国疫苗和免疫,2010,16(6):496-499.
Zheng H, **Cui F**, Gong X, Wang F, Chen Y, Wu Z, Wang H, Li L, Luo H, Liang X. Status of the hepatitis B virus surface antigen and e antigen prevalence among reproductive women in China. Chinese Journal of Vaccines and Immunization. 2010,16(6):496-499.
120. 刘燕敏,陈园生,**崔富强**,王富珍,郑徽,吴振华,缪宁,罗会明,梁晓峰,龚晓红.中国 2004~2009 年甲型病毒性肝炎流行病学特征分析.中国疫苗和免疫,2010,16(5):453-456.
Liu Y, Chen Y, **Cui F**, Wang F, Zheng H, Wu Z, Miao N, Luo H, Liang X, Gong X. Epidemiological analysis of hepatitis A in China during 2004-2009. Chinese Journal of Vaccines and Immunization. 2010, 16(5):453-456.
121. 郑徽,**崔富强**,龚晓红,王富珍,陈园生,吴振华,张卫,董红军,邵晓萍,张勇,梁晓峰.5 微克重组乙型肝炎疫苗(酵母) 3 剂初次免疫后低/无应答儿童再免 1 剂的抗体应答.中国疫苗和免疫,2010,16(5):443-446.

Zheng H, **Cui F**, Gong X, Wang F, Chen Y, Wu Z, Zhang W, Dong H, Shao X, Zhang Y, Liang X. Revaccination of one dose recombinant yeast derived hepatitis B vaccine to the antibody respond of low-and-nonresponders. Chinese Journal of Vaccines and Immunization. 2010,16(5):443-446.

122. 漆可发,李慧,高丽,张晓曙,**崔富强**,Yoshihiro Takashima,倪大新,彭博识.定西市 2005 年出生儿童乙型肝炎疫苗首针及时接种率及影响因素调查.卫生软科学,2010,24(2):145-148.
Qi K, Li H, Gao L, Zhang X, **Cui F**, Yoshihiro Takashima, Ni D, Peng B. Study on the timely birth dose of hepatitis B vaccine and the influencing factors among children born in 2005 in Dingxi prefecture. Soft Science of Health,2010,24(2):145-148.

2009 年

123. Liang X, Bi S, Yang W, Wang L, Cui G, **Cui F**, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler S, Wang Y. Evaluation of the Impact of Hepatitis B Vaccination among Children Born during 1992 and 2005 in China. Journal of Infectious disease, 2009,200(1):39-47.
梁晓峰,毕胜利,杨维中,王陇德,崔钢,**崔富强**,张勇,刘甲也,龚晓红,陈园生,王富珍,郑徽,王峰,郭靖,贾志远,马景辰,王华庆,罗会明,李黎,金水高,Stephen C Hadler,王宇.中国 1992~2005 年出生儿童接种乙肝疫苗效果评价. Journal of Infectious disease, 2009,200(1):39-47.
124. Liang X, Bi S, Yang W, Wang L, Cui G, **Cui F**, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Wang F, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler S, Wang Y. Epidemiological Serosurvey of Hepatitis B in China - Declining HBV Prevalence due to Hepatitis B Vaccination. Vaccine, 2009, 27:6550-6557.
梁晓峰,毕胜利,杨维中,王陇德,崔钢,**崔富强**,张勇,刘甲也,龚晓红,陈园生,王富珍,郑徽,王峰,郭靖,贾志远,马景辰,王华庆,罗会明,李黎,金水高,Stephen C Hadler,王宇. 中国乙型肝炎病毒性肝炎血清流行病学调查—通过新生儿乙型肝炎疫苗免疫策略降低乙型肝炎病毒流行率. Vaccine, 2009, 27:6550-6557.
125. 王富珍,**崔富强**,刘大卫,龚晓红,郑徽,陈园生,梁晓峰. 接种乙型肝炎疫苗后 10 例婴儿死亡的疑似预防接种异常反应分析.中国疫苗和免疫,2009,15 (1): 52-57.
Wang F, **Cui F**, Liu D, Gong X, Zheng H, Chen Y, Liang X. Analysis on the adverse events following immunization of 10 infants death after hepatitis B vaccination. Chinese Journal of Vaccines and Immunization, 2009,15 (1): 52-57.
126. 郑徽,**崔富强**.甲型肝炎减毒活疫苗与灭活疫苗免疫原性及其影响因素.中国疫苗和免疫,2009,15 (4): 371-374.
Zheng H, **Cui F**. The immunogenicity and impact factors of hepatitis A attenuated live vaccine and inactivated vaccine. Chinese Journal of Vaccines and Immunization, 2009,15 (4): 371-374.
127. 党如波,张顺祥,张卫东,梁晓峰,**崔富强**,赵飞. 中国新生儿乙肝疫苗免疫效果评估, 中国公共卫生,2009,25(4): 385-387.
Dang R, Zhang S, Zhang W, Liang X, **Cui F**, Zhao F. Assessment for immune effectiveness of hepatitis B vaccination among infant population in China. Chin J Public Health., 2009,25(4): 385-387.

2008 年

128. 张顺祥,党如波,张卫东,梁晓峰,**崔富强**.中国乙型肝炎疫苗免疫预防效果和现行策略的经

济学和决策学评估.中华流行病学杂志,2008,29(10):1003-1008.

Zhang S, Dang R, Zhang W, Liang X, **Cui F**. Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China. *Chin J Epidemiol*, 2008,29(10):1003-1008.

129. 陈园生,李放军,王晓军,王富珍,**崔富强**,龚晓红,郑徽,曾绍长,赵建海,谢晋尧,陈长,夏伟,孙莲英,张永基,肖娜,胡苑笙,吴振华,梁晓峰.公共服务场所乙型肝炎病毒感染危险性研究.中华流行病学杂志,2008,29(7):689-692.

Chen Y, Li F, Wang X, Wang F, **Cui F**, Gong X, Zheng H, Zeng S, Zhao J, Xie J, Chen C, Xia W, Sun L, Zhang Y, Xiao N, Hu Y, Wu Z, Liang X. Study on the probability of hepatitis B virus infection at public service places. *Chin J Epidemiol*, 2008,29(7):689-692.

130. 吴振华,**崔富强**,龚晓红,陈园生,王富珍,郑徽,胡苑笙,梁晓峰.新生儿接种乙型肝炎疫苗后低/无应答的影响因素.中国疫苗和免疫,2008,14(5):464-469.

Wu Z, **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Hu Y, Liang X. Influential factors of non-and-low response after hepatitis B vaccination to infants. *Chinese journal of vaccine and immunization*, 2008,14(5):464-469.

131. 陈园生,周玉清,王晓军,陈长,李放军,王富珍,曾绍长,赵建海,谢晋尧,**崔富强**,龚晓红,郑徽,夏伟,孙莲英,张永基,肖娜,胡苑笙,吴振华,曹玲生,梁晓峰,胡俊峰.公共服务场所器械消毒与乙型肝炎病毒污染现况调查.中国疫苗和免疫,2008,14(4):315-318.

Chen Y, Zhou Y, Wang X, Chen C, Li F, Wang F, Zeng S, Zhao J, Xie J, **Cui F**, Gong X, Zheng H, Xia W, Sun L, Zhang Y, Xiao N, Hu Y, Wu Z, Cao L, Liang X, Hu J. Study on the status of sanitizing and HBV contamination of appliances used in the public service places. *Chinese journal of vaccine and immunization*, 2008,14(4):315-318.

132. 梁晓峰,杨超美,罗会明,王华庆,**崔富强**,李艺星,杜飞,安志杰,殷大鹏,刘大卫,曹玲生 尹遵栋,郑徽,杨峰,崔钢,杨维中.四川省地震灾区甲型肝炎疫苗和流行性乙型脑炎减毒活疫苗群体性预防接种分析.中国疫苗和免疫,2008,14(4):289-291.

Liang X, Yang C, Luo H, Wang H, **Cui F**, Li Y, Du F, An Z, Yin D, Liu D, Cao L, Yin Z, Zheng H, Yang F, Cui G, Yang W. Analysis on mass vaccination campaign of hepatitis A vaccine and live Japanese Encephalitis vaccine in earthquake areas in Sichuan. *Chinese journal of vaccine and immunization*, 2008,14(4):289-291.

133. 胡苑笙,张永基,万玛加,李承宁,李秀芹,**崔富强**,龚晓红,陈园生,王富珍,郑徽,梁晓峰. 黄南藏族自治州提高新生儿乙型肝炎疫苗首针及时接种率项目可持续发展评价.中国疫苗和免疫,2008,14(2):147-149.

Hu Y, Zhang Y, Wan M, Li C, Li X, **Cui F**, Gong X, Chen Y, Wang F, Zheng H, Liang X. Evaluation of sustainability of the project of improving timely birth dose of hepatitis B vaccine in Tibetan autonomous prefecture of Huangnan. *Chinese journal of vaccine and immunization*, 2008,14(2):147-149.

2007 年

134. 随海田,梁晓峰,殷大鹏,**崔富强**,王华庆. 中国 1990~2006 年甲型病毒性肝炎流行病学特征分析, 中国计划免疫,2007, 13(5):466-469.

Sui H, Liang X, Yin D, **Cui F**, Wang H. Epidemic characteristics on Hepatitis A in China during 1990~2006. *Chinese Journal of Vaccines and Immunization*,2007, 13(5):466-469.

135. 郑徽,卢永,王富珍,**崔富强**.中国 2004~2006 年甲型病毒性肝炎疫情分析,中国计划免疫,2007,13(4): 336-340.

- Zheng H, Lu Y, Wang F, **Cui F**. Epidemiological analysis on Hepatitis A in China during 2004~2006. Chinese Journal of Vaccines and Immunization. 2007, 13(4): 336-340.
136. 王富珍, **崔富强**, 卢永, 陈园生, 郑徽, 梁晓峰. 中国 8 个省 18 个县(区)乙型病毒性肝炎监测病例分析, 中国计划免疫, 2007, 13(4): 309-312.
- Wang F, **Cui F**, Lu Y, Chen Y, Zheng H, Liang X. Analysis on reported Hepatitis B cases on pilot surveillance in 18 counties of 8 provinces of China. Chinese Journal of Vaccines and Immunization, 2007, 13(4): 309-312.
137. 王富珍, **崔富强**, 郑徽, 陈园生, 李继军, 龚晓红, 方挺, 高丽, 张勇, 梁晓峰. 重组乙型肝炎疫苗(酵母)与乙型肝炎免疫球蛋白联合免疫阻断乙型肝炎病毒母婴传播的效果分析. 中国计划免疫, 2007, 13(4): 293-297.
- Wang F, **Cui F**, Zheng H, Chen Y, Li J, Gong X, Fang T, Gao L, Zhang Y, Liang X. Evaluation on protective efficacy of recombinant yeast derived Hepatitis B vaccines combination with Hepatitis B immune globulin in preventing mother-to-infant transmission of Hepatitis B virus. Chinese Journal of Vaccines and Immunization, 2007, 13(4): 293-297.
138. 李秀芹, 万玛加, 李青旗, 李承宁, 胡苑笙, 张永基, 乔华, 王建仁, 马耀军, **崔富强**, 梁晓峰, 倪大新, Yoshihiro Takashim. 健康教育对提高农牧区新生儿乙型肝炎疫苗首针及时接种率的效果分析. 中国计划免疫, 2007, 13(1): 43-45.
- Li X, Wan M, Li Q, Li C, Hu Y, Zhang Y, Qiao H, Wang J, Ma Y, **Cui F**, Liang X, Ni D, Yoshihiro Takashima. Analysis on health education on improving the timely-birth dose coverage of Hepatitis B in rural and pasturing areas in Qinghai province. Chinese Journal of Vaccines and Immunization, 2007, 13(1): 43-45.
139. 张永基, 胡苑笙, 张昕伟, 石西安, 万玛加, 李青旗, 李承宁, 李秀芹, **崔富强**, 梁晓峰, 倪大新 Yoshihiro Takashim. 黄南藏族自治州提高新生儿乙型肝炎疫苗首针及时接种率及影响因素调查. 中国计划免疫, 2007, 13(1): 40-42.
- Zhang Y, Hu Y, Zhang X, Shi X, Wan M, Li Q, Li C, Li X, **Cui F**, Liang X, Ni D, Yoshihiro Takashima. Strategy on improving the birth-time coverage in Huangnan prefecture of Qinghai province. Chinese Journal of Vaccines and Immunization, 2007, 13(1): 40-42.
140. 李承宁, 万玛加, 李秀芹, 张永基, 张昕伟, 巴文生, 李青旗, 乔华, 胡苑笙, 马耀军, **崔富强**, 梁晓峰, Yoshihiro Takashima, 倪大新. 黄南藏族自治州 2004 年新生儿乙型肝炎疫苗首针及时接种率及影响因素调查. 中国计划免疫, 2007, 13(1): 37-39.
- Li C, Wan M, Li X, Zhang Y, Zhang X, Ba W, Li Q, Qiao H, Ma Y, **Cui F**, Liang X, Yoshihiro Takashima, Ni D. Study on birth-time coverage and correlative factors in Huangnan prefecture of Qinghai province in 2004. Chinese Journal of Vaccines and Immunization, 2007, 13(1): 37-39.
141. 陈园生, 王晓军, 李艺星, **崔富强**, 梁晓峰. 慢性乙型病毒性肝炎患病率调查方法的探讨. 中国计划免疫, 2007; 13(1): 27-29.
- Chen Y, Wang X, Li Y, **Cui F**, Liang X. Analysis on the Investigation about the prevalence rate of chronic HBV infection. Chinese Journal of Vaccines and Immunization, 2007; 13(1): 27-29.

2006 年

142. 卢永, **崔富强**, 王晓军, 龚晓红, 董红军, 胡苑笙, 陈园生, 梁晓峰. 中国八省市各级医疗机构确诊急性乙型肝炎实验室检测能力调查. 中华流行病学杂志, 2006, 27(9): 802-804

Lu Y, Cui F, Wang X, Gong X, Dong H, Hu Y, Chen Y, Liang X. Capacity of laboratory testing for acute hepatitis B in medical setting in 8 provinces in China. Chinese Journal of Epidemiology, 2006, 27 (9):802-804.

143. 胡苑笙,王晓军,陈园生,陆伟,张荣珍,崔富强,李军宏,周玉清,卢永,朱冰,梁晓峰,中国中西部地区新生儿乙型肝炎疫苗首针及时接种状况调查.中国计划免疫,2006, 12 (2): 206-208
Hu Y, Wang X, Chen Y, Lu W, Zhang R, Cui F, Li J, Zhou Y, Lu Y, Zhu B, Liang X. Study on Hepatitis B birth dose coverage in the western and mid-level provinces of China. Chinese Journal of Vaccines and Immunization, 2006, 12 (2): 206-208.
144. 高丽,李慧,张晓曙,崔富强,刘建地,唐宇,李晓波,王晓玲,卢欣婷.甘肃省部分县乙型肝炎疫苗免疫接种率及影响因素调查.中国计划免疫,2006,12(2):106-108.
Gao L, Li H, Zhang X, Cui F, Liu J, Tang Y, Li X, Wang X, Lu X. Analysis on immunization coverage rate and affecting factors of Hepatitis B vaccine among children in Gansu province in 2001-2003. Chinese Journal of Vaccines and Immunization, 2006, 12(2):106-108.

2005 年

145. 张宁静,付鸿,李慧,崔富强.甘肃省 2003 年麻疹监测流行病学分析.中国计划免疫,2005,11(3): 192-194.
Zhang N, Fu H, Li H, Cui F. Analysis on the Epidemiology of measles surveillance in 2003 in Gansu province. Chinese Journal of Vaccines and Immunization,2005, 11(3):192-194.
146. 李慧,李凤琴,甄晓荣,吴照,唐宇,崔富强,张宁静,刘建锋,付鸿,王晓玲,高丽,张晓曙,李晓波.甘肃省 2003 年保持无脊髓灰质炎状态进展.中国计划免疫,2005,11(1):61-63.
Li H, Li F, Zhen X, Wu Z, Tang Y, Cui F, Zhang N, Liu J, Fu H, Wang X, Gao L, Zhang X, Li X. Progress of maintaining polio-free status in Gansu. Chinese Journal of Vaccines and Immunization,2005, 11(1): 61-63.
147. 张宁静,付鸿,李慧,崔富强.甘肃省 2003 年麻疹监测流行病学分析.中国计划免疫,2005,11(3):
Zhang N, Fu H, Li H, Cui F. 甘肃省 2003 年麻疹监测流行病学分析.中国计划免疫,2005,11(3)(未下载到文献)

2004 年

148. 石川尚子,郝利新,张振喜,崔富强,李慧. 婴儿出生后 24 小时内乙型肝炎疫苗低接种率的原因及居民教育,中国计划免疫, 2004,10(3): 138-141.
Ishikawa N, Hao L, Zhang Z, Cui F, Li H. The factors affecting the low coverage rate of hepatitis B vaccine at birth and the role of health education in Gansu province, China. Chinese Journal of Vaccines and Immunization,2004,10(3):138-141.
149. 张宁静,付红,李慧,崔富强.甘肃省 2003 年麻疹监测数据分析评价.卫生职业教育,2004,22(17):113.
Zhang N, Fu H, Li H, Cui F. Analysis and evaluation on measles surveillance data of Gansu province in 2003. Health Vocational Education,2004,22(17):113.

2003 年

150. 李慧,邸宏杰,付鸿,崔富强,高丽,孙延玲.甘肃省部分地区麻疹疫苗强化免疫效果评价.中国公共卫生, 2003,19(6):739.

Li H, Zhi H, Fu H, **Cui F**, Gao L, Sun Y. Evaluation on efficacy of measles vaccine immunization campaign in partial areas of Gansu province. Chin J Public Health, 2003,19(6):739.

151. 李慧,付鸿,邸宏杰,**崔富强**,孙延玲,刘建地.甘肃省部分地区麻疹疫苗强化免疫血清学效果评价[J].中国计划免疫,2003,9(5):266-268.

Li H, Fu H, Di H, **Cui F**, Sun Y, Liu J. Evaluation on serological efficacy of measles vaccine immunization campaign in partial areas of Gansu province. Chinese Journal of Vaccines and Immunization, 2003,9(5):266-268.

152. 孟蕾,李慧,刘建地,高丽,**崔富强**,卢欣婷.甘肃省乙型肝炎流行病学特征和控制策略.中国计划免疫,2003,9(6): 326-328.

Meng L, Li H, Liu J, Gao L, **Cui F**, Lu X. The epidemiological features of hepatitis B in Gansu province and the control strategy. Chinese Journal of Vaccines and Immunization, 2003,9(6): 326-328.

2002年

153. 何庚声,李慧,崔富强,邸宏杰,付鸿,李凤琴,刘建地,邵爱红.甘肃省不同经济状况地区儿童计划免疫接种情况及影响因素分析.中国计划免疫,2002,8(4):217-219.

He G, Li H, Cui F, Zhi H, Fu H, Li F, Liu J, Shao A. An analysis on immunization coverage rate of Children in different economic developing areas in Gansu Province. Chinese Journal of Vaccines and Immunization, 2002,8(4):217-219.

2001年

154. 李慧,何庚声,**崔富强**,刘建地,李凤琴,石华峰.甘肃省基层计划免疫服务现状调查.中国计划免疫,2001,7(3):172-174.

Li H, He G, **Cui F**, Liu J, Li F, Shi H. Investigation on immunization serves at grass root level in Gansu province. Chinese Journal of Vaccines and Immunization, 2001,7(3):172-174.

155. 李慧,何庚声,**崔富强**.甘肃省不同经济状况地区预防接种安全注射现状调查.中国计划免疫,2001,7(4): 218-220.

Li H, He G, **Cui F**. An investigation on present situation of safe injection of immunization service in different economic areas in Gansu province. Chinese Journal of Vaccines and Immunization, 2001,7(4): 218-220.

参与重大公共卫生事件调查处理

2006年西藏察隅麻疹暴发

2007年云南接种乙肝疫苗后不明原因死亡

2008年汶川地震群体性预防接种

2009年广东、福建、山东甲流疫情处置

2010年参与山西疫苗事件调查处理

2011年脊灰输入野病毒疫情(新疆和田、喀什)

2013年乙肝疫苗媒体事件的调查处置

2016年山东非法经营疫苗系列案件调查处置

在国际会议上的报告

1. Panelist of Prevention: Elimination of mother-to-child transmission (EMTCT of HBV) and Chair person of Surveillance and data management. Eexpert consultation for viral hepatitis elimination in the western pacific region. 1-3 December 2020 Manila. Western Pacific Region of World Health Organization.
2. The latest development of Covid-19 vaccine. Fifth Annual QU Health Research Symposium. 14 November 2020. Qatar & PKU.
3. Global and regional progress towards hepatitis elimination. 29-30 June 2020, Geneva, WHO Validation meeting on hepatitis elimination as a public health threat: Part 1.
4. Latest developments in global hepatitis B control. Third Consultation of the South-East Asia Regional Expert Panel for Verification of Hepatitis B Control (SEA-REP) New Delhi, India, 20-21 January 2020.
5. China's work towards elimination of hepatitis B virus. Sixth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation. World Health Organization, West Pacific Region Office, Sep 18, 2018. Manila, Philippine.
6. Fostering collaboration among MCH, NIP and HSI in China. Sixth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation. World Health Organization, West Pacific Region Office, Sep 18, 2018. Manila, Philippine.
7. Developing a Healthcare Worker Vaccination Programme in China. Sixth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation. World Health Organization, West Pacific Region Office, Sep 18, 2018. Manila, Philippine.
8. New Development of Preventing Mother-to Child HBV Transmission in China. Fifth Hepatitis B Immunization Expert Resource Panel (ERP) Consultation WHO WPRO ERP, Manila, Philippine. 2017
9. What Can We Learn from Hepatitis B and C Control in China, Current Progress and Future Considerations? First Meeting of Hepatitis Programme Focal Points from High –burden Countries in Asia. Hong Kong SAR (China), June 22-24, 2016. Hong Kong, China.
10. What Can We Learn from Hepatitis B Control in China? The 3rd International Symposium on Viral Hepatitis. June 22-24, 2016. Chengdu, China.
11. Review of 2014 sero-survey results and next steps in hepatitis B control in China, 2014. January 25-27, 2016. Hanoi, Viet Nam
12. Introduction on China's National Immunization Programme, Chairperson and Speaker on The Second China-Czech Health Forum, session of Public Health: Priority of Czech-China Health Cooperation June 20, 2014. Beijing, China.
13. Measles Elimination in China: Strategies, Progress, Challenges and Action Plans. World Health Organization SAGE Decade of Vaccines Working Group Meeting. 18-20 February 2014, WHO HQ Geneva.
14. Progress and challenges to Care: Treatment, management, and care strategies in China. HCV Treatment and care in vulnerable populations: Challenges, opportunities and future directions, November 7-7, 2013. Ottawa, Canada.

15. Scaling up hepatitis B vaccination with the support of GAVI in China: Lessons learned for introduction of new vaccines and for the future of hepatitis B control. Life & Health R&D Forum: infectious diseases and vaccination, Beijing China, August 15,2013.
16. Viral Hepatitis surveillance in China. Technical Consultation to Develop Guidelines for the Surveillance of Viral Hepatitis in Low- and Middle-income Countries. World Health Organization Headquarters, Geneva, 25-27 March 2013
17. Chinese Experience on Improving Hepatitis B vaccine Time Birth Dose of Public Health Innovation through Collaboration. Guest speaker for CDC-China Focus, 23 January 2013, Beijing American Center, Beijing, China
18. Progress toward Measles Elimination in China. 21th Technical Advisory Expert Group Meeting on Vaccines and Vaccine preventable Disease in WPRO. 21–23 August 2012, Manila, Philippines
19. Overview of China Experience with Increasing Timely Birth Dose. Consultation on improving and monitoring Hepatitis B birth dose. 13-15 June 2012, WPRO, Manila, Philippines
20. Progress toward Measles Elimination in China: Achievement and Challenges. WHO Western Pacific Region Technical Advisory Group meeting, 9 August, 2011, Manila, Philippine.
21. Experience with measles elimination in high epidemic areas in China. WHO Western Pacific Region Technical Advisory Group meeting, 9 August, 2011, Manila, Philippine.
22. Consultation on Best Practices and Tools for Preventing Perinatal Hepatitis B Virus Transmission. Burnet Institute, Melbourne, Australia, 7-8 December 2010.
23. Post-marketing surveillance of the live attenuated hepatitis A vaccines in China, Global Advisory Committee on Vaccine Safety, 16-17 June 2010, Geneva.
24. Evaluation plans for GAVI project in China, and catch up vaccination in children, Asia and viral hepatitis: Learning from China to enhance prevention and control efforts in Asia. April 28, 2010, Hongkong, China
25. Impact of hepatitis A vaccine use on disease incidence in China, Asia and viral hepatitis: Learning from China to enhance prevention and control efforts in Asia. April 28, 2010, Hongkong, China
26. Hepatitis B control, Strategies, successes and challenges in China. Scientific seminar on hepatitis B, 26-27 Jan 2010, Hanoi, Vietnam.
27. Progress of Measles Control in China, Global Measles Management Meeting, 20 February, 2009, New York, USA.
28. Evaluation on Health Promotion Program in China, 11 Feb, 2009. Hong Kong.
29. Hepatitis B in China: Example of How to Tackle Discrimination, Asia Summit on Corporate society Responsibility, 3 Nov, 2008, Thailand.
30. Achievability of Regional Goal - Strategies, Successes and Challenges, WPRO Technical Advisory Group meeting, 27 June, 2007, Manila, Philippine.
31. Operational Features of China - Hepatitis B Immunization Program, WPRO Technical Advisory Group meeting, 20 June, 2006, Manila, Philippine.

32. Improving Hepatitis B Immunization Rates in China, 12th International Conference for Hepatitis, 4 July, 2006, Paris, France.
33. Hepatitis B Vaccination in China, Annual Meeting of Asian and Pacific Association of Study of Liver, 17 August, 2005, Bali, Indonesia.